{ "instance": { "sln-20221231.htm": { "axisCustom": 0, "axisStandard": 27, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 41, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 902 }, "contextCount": 338, "dts": { "calculationLink": { "local": [ "sln-20221231_cal.xml" ] }, "definitionLink": { "local": [ "sln-20221231_def.xml" ] }, "inline": { "local": [ "sln-20221231.htm" ] }, "labelLink": { "local": [ "sln-20221231_lab.xml" ] }, "presentationLink": { "local": [ "sln-20221231_pre.xml" ] }, "schema": { "local": [ "sln-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 622, "entityCount": 1, "hidden": { "http://silence-therapeutics.com/20221231": 5, "http://xbrl.sec.gov/dei/2022": 3, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 2, "total": 10 }, "keyCustom": 100, "keyStandard": 239, "memberCustom": 66, "memberStandard": 29, "nsprefix": "sln", "nsuri": "http://silence-therapeutics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Segment reporting", "menuCat": "Notes", "order": "10", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReporting", "shortName": "Segment reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Share Capital - Summary of Share Capital (Details)", "menuCat": "Details", "order": "100", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfShareCapitalDetails", "shortName": "Share Capital - Summary of Share Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_d896965b-f036-4778-960c-af33a3ecd3f1", "decimals": "-3", "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101020 - Disclosure - Share Capital - Summary of Share Capital (Parenthetical) (Details)", "menuCat": "Details", "order": "101", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails", "shortName": "Share Capital - Summary of Share Capital (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R102": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_d896965b-f036-4778-960c-af33a3ecd3f1", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Share Capital - Additional Information (Details)", "menuCat": "Details", "order": "102", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "shortName": "Share Capital - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c54fd263-fa02-4c4c-8fa5-f359bf4ef8c0", "decimals": "6", "lang": null, "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101040 - Disclosure - Share Capital - Summary of Details of Shares Issued (Details)", "menuCat": "Details", "order": "103", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "shortName": "Share Capital - Summary of Details of Shares Issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "lang": null, "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_9e44b643-6068-4c1a-948d-27a06e319968", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101050 - Disclosure - Share Capital - Summary of Details of Shares Issued (Parenthetical) (Details)", "menuCat": "Details", "order": "104", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "shortName": "Share Capital - Summary of Details of Shares Issued (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_9e44b643-6068-4c1a-948d-27a06e319968", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101060 - Disclosure - Share Capital - Summary of Options Outstanding (Details)", "menuCat": "Details", "order": "105", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails", "shortName": "Share Capital - Summary of Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e40ff14c-5397-43a1-9941-11bdb4a17f5e", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101070 - Disclosure - Equity-settled share-based payments - Summary of Options (Details)", "menuCat": "Details", "order": "106", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "shortName": "Equity-settled share-based payments - Summary of Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_d896965b-f036-4778-960c-af33a3ecd3f1", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101080 - Disclosure - Equity-settled share-based payments - Additional Information (Details)", "menuCat": "Details", "order": "107", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "shortName": "Equity-settled share-based payments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageSharePrice2019", "reportCount": 1, "unique": true, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101090 - Disclosure - Equity-settled share-based payments - Summery of Fair Value of Options Granted, Calculated Using Binomial or Monte Carlo Model and Inputs Into the Model (Details)", "menuCat": "Details", "order": "108", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails", "shortName": "Equity-settled share-based payments - Summery of Fair Value of Options Granted, Calculated Using Binomial or Monte Carlo Model and Inputs Into the Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageSharePrice2019", "reportCount": 1, "unique": true, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unitRef": "U_U_iso4217GBP_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101100 - Disclosure - Capital Reserves - Additional Information (Details)", "menuCat": "Details", "order": "109", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "shortName": "Capital Reserves - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "INF", "lang": null, "name": "sln:DistributableReserves", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Operating loss", "menuCat": "Notes", "order": "11", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLoss", "shortName": "Operating loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101110 - Disclosure - Capital Reserves - Summary of Capital Reserves (Details)", "menuCat": "Details", "order": "110", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails", "shortName": "Capital Reserves - Summary of Capital Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutCapitalReservesExplanatory", "div", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_1b0bc5b5-a505-4e73-99b6-98ca0216cc80", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:CapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101120 - Disclosure - Capital Commitments and Contingent Liabilities - Additional Information (Details)", "menuCat": "Details", "order": "111", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails", "shortName": "Capital Commitments and Contingent Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:CapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "p", "sln:DisclosureOfCommitmentsUnderShortLeasesTextBlock", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-5", "first": true, "lang": null, "name": "sln:CommitmentOnOfficeRentalAndServiceCharge", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101130 - Disclosure - Commitments under short leases - Additional Information (Details)", "menuCat": "Details", "order": "112", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails", "shortName": "Commitments under short leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "sln:DisclosureOfCommitmentsUnderShortLeasesTextBlock", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-5", "first": true, "lang": null, "name": "sln:CommitmentOnOfficeRentalAndServiceCharge", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101140 - Disclosure - Financial instruments and risk management - Summary of Categories of Financial Assets (Details)", "menuCat": "Details", "order": "113", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "shortName": "Financial instruments and risk management - Summary of Categories of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_95ed9085-e815-4b35-8cd7-e677e97e201b", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilities", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101150 - Disclosure - Financial instruments and risk management - Summary of Financial Liabilities by Category (Details)", "menuCat": "Details", "order": "114", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails", "shortName": "Financial instruments and risk management - Summary of Financial Liabilities by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_144076c0-adac-4ec7-9c0c-3470d6d29751", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutFinancialAssetsAtAmortizedCostExplanatory", "div", "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101160 - Disclosure - Financial instruments and risk management - Summary of Credit Quality of Financial Assets (Details)", "menuCat": "Details", "order": "115", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails", "shortName": "Financial instruments and risk management - Summary of Credit Quality of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfCreditRiskExposureExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_a5a877e5-126e-45d2-8fd0-f0214b9c5428", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_3e86a764-35f8-41e1-b80c-b2210dff4039", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:UndiscountedFinanceLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101170 - Disclosure - Financial instruments and risk management - Additional Information (Details)", "menuCat": "Details", "order": "116", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "shortName": "Financial instruments and risk management - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_3e86a764-35f8-41e1-b80c-b2210dff4039", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:UndiscountedFinanceLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101180 - Disclosure - Financial instruments and risk management - Summary of Financial Assets and Liabilities Denominated in Euros and Translated into Sterling at Closing Rate (Details)", "menuCat": "Details", "order": "117", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "shortName": "Financial instruments and risk management - Summary of Financial Assets and Liabilities Denominated in Euros and Translated into Sterling at Closing Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfCurrencyRiskExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_649ac422-1b4b-4ded-aac1-d8c3dc330aaf", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101190 - Disclosure - Financial instruments and risk management - Summary of Impact of Additional Weakening or Strengthening of Sterling Against Euro (Details)", "menuCat": "Details", "order": "118", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "shortName": "Financial instruments and risk management - Summary of Impact of Additional Weakening or Strengthening of Sterling Against Euro (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_dded8929-b617-4913-aee0-5b16ae3e61c9", "decimals": "-3", "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101200 - Disclosure - Financial instruments and risk management - Summary of Impact of Additional Weakening or Strengthening of Sterling Against U.S. Dollar (Details)", "menuCat": "Details", "order": "119", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails", "shortName": "Financial instruments and risk management - Summary of Impact of Additional Weakening or Strengthening of Sterling Against U.S. Dollar (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_23198555-7001-4234-a243-f5ceb814cab5", "decimals": "-3", "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Directors and staff costs", "menuCat": "Notes", "order": "12", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCosts", "shortName": "Directors and staff costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101210 - Disclosure - Notes to the cash flow statement - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "menuCat": "Details", "order": "120", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "shortName": "Notes to the cash flow statement - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_916fbc0c-0e76-474a-b459-a0ef7d9c9b9f", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101220 - Disclosure - Related party transactions - Additional Information (Details)", "menuCat": "Details", "order": "121", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related party transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_916fbc0c-0e76-474a-b459-a0ef7d9c9b9f", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfOtherLossesGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Other losses", "menuCat": "Notes", "order": "13", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLosses", "shortName": "Other losses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfOtherLossesGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Finance and other expenses", "menuCat": "Notes", "order": "14", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpenses", "shortName": "Finance and other expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Finance and other income", "menuCat": "Notes", "order": "15", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncome", "shortName": "Finance and other income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Taxation", "menuCat": "Notes", "order": "16", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxation", "shortName": "Taxation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Loss per ordinary equity share (basic and diluted)", "menuCat": "Notes", "order": "17", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLossPerOrdinaryEquityShareBasicAndDiluted", "shortName": "Loss per ordinary equity share (basic and diluted)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Property, plant and equipment", "menuCat": "Notes", "order": "18", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "shortName": "Property, plant and equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Goodwill", "menuCat": "Notes", "order": "19", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED INCOME STATEMENTS", "menuCat": "Statements", "order": "2", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS", "shortName": "CONSOLIDATED INCOME STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Other intangible assets", "menuCat": "Notes", "order": "20", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssets", "shortName": "Other intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Cash and cash equivalents", "menuCat": "Notes", "order": "21", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalents", "shortName": "Cash and cash equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Derivative Financial Instruments", "menuCat": "Notes", "order": "22", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Financial assets at amortized cost", "menuCat": "Notes", "order": "23", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCost", "shortName": "Financial assets at amortized cost", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Other current assets", "menuCat": "Notes", "order": "24", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssets", "shortName": "Other current assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Trade receivables", "menuCat": "Notes", "order": "25", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivables", "shortName": "Trade receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Trade and other payables", "menuCat": "Notes", "order": "26", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayables", "shortName": "Trade and other payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Lease liability", "menuCat": "Notes", "order": "27", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiability", "shortName": "Lease liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Contract liabilities", "menuCat": "Notes", "order": "28", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilities", "shortName": "Contract liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Deferred tax", "menuCat": "Notes", "order": "29", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTax", "shortName": "Deferred tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "3", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Share capital", "menuCat": "Notes", "order": "30", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapital", "shortName": "Share capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Equity-settled share-based payments", "menuCat": "Notes", "order": "31", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPayments", "shortName": "Equity-settled share-based payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Capital reserves", "menuCat": "Notes", "order": "32", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReserves", "shortName": "Capital reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Capital commitments and contingent liabilities", "menuCat": "Notes", "order": "33", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalCommitmentsAndContingentLiabilities", "shortName": "Capital commitments and contingent liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfCommitmentsUnderShortLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Commitments under short leases", "menuCat": "Notes", "order": "34", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeases", "shortName": "Commitments under short leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfCommitmentsUnderShortLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Financial instruments and risk management", "menuCat": "Notes", "order": "35", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement", "shortName": "Financial instruments and risk management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Notes to the cash flow statement", "menuCat": "Notes", "order": "36", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatement", "shortName": "Notes to the cash flow statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Related party transactions", "menuCat": "Notes", "order": "37", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Post Balance Sheet Events", "menuCat": "Notes", "order": "38", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePostBalanceSheetEvents", "shortName": "Post Balance Sheet Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Principal accounting policies (Policies)", "menuCat": "Policies", "order": "39", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies", "shortName": "Principal accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "4", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "40", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Segment reporting (Tables)", "menuCat": "Tables", "order": "41", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingTables", "shortName": "Segment reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:SummaryOfOperatingLossExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Operating loss (Tables)", "menuCat": "Tables", "order": "42", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossTables", "shortName": "Operating loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:SummaryOfOperatingLossExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Directors and staff costs (Tables)", "menuCat": "Tables", "order": "43", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsTables", "shortName": "Directors and staff costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "sln:DisclosureOfOtherLossesGainsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfSummaryOfOtherLossesGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Other losses (Tables)", "menuCat": "Tables", "order": "44", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesTables", "shortName": "Other losses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "sln:DisclosureOfOtherLossesGainsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfSummaryOfOtherLossesGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Finance and other expenses (Tables)", "menuCat": "Tables", "order": "45", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesTables", "shortName": "Finance and other expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:SummaryOfFinanceAndOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Finance and other income (Tables)", "menuCat": "Tables", "order": "46", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeTables", "shortName": "Finance and other income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:SummaryOfFinanceAndOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfComponentsOfTaxationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Taxation (Tables)", "menuCat": "Tables", "order": "47", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationTables", "shortName": "Taxation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfComponentsOfTaxationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Property, plant and equipment (Tables)", "menuCat": "Tables", "order": "48", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, plant and equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Goodwill (Tables)", "menuCat": "Tables", "order": "49", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillTables", "shortName": "Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_cc177deb-7de0-43d0-8a00-fb8ec15ccb16", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "menuCat": "Statements", "order": "5", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_fea90e01-20d8-46e6-b4f2-bb8017fdeef3", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Other Intangible Assets (Tables)", "menuCat": "Tables", "order": "50", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsTables", "shortName": "Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Cash and cash equivalents (Tables)", "menuCat": "Tables", "order": "51", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and cash equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutFinancialAssetsAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Financial assets at amortized cost (Tables)", "menuCat": "Tables", "order": "52", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostTables", "shortName": "Financial assets at amortized cost (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutFinancialAssetsAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Other current assets (Tables)", "menuCat": "Tables", "order": "53", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsTables", "shortName": "Other current assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationOfTradeReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Trade receivables (Tables)", "menuCat": "Tables", "order": "54", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesTables", "shortName": "Trade receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationOfTradeReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Trade and other payables (Tables)", "menuCat": "Tables", "order": "55", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesTables", "shortName": "Trade and other payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:ScheduleOfLeaseLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Lease liability (Tables)", "menuCat": "Tables", "order": "56", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityTables", "shortName": "Lease liability (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:ScheduleOfLeaseLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfContractLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Contract liabilities (Tables)", "menuCat": "Tables", "order": "57", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesTables", "shortName": "Contract liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfContractLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Deferred tax (Tables)", "menuCat": "Tables", "order": "58", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxTables", "shortName": "Deferred tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Share capital (Tables)", "menuCat": "Tables", "order": "59", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalTables", "shortName": "Share capital (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED CASH FLOW STATEMENTS", "menuCat": "Statements", "order": "6", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS", "shortName": "CONSOLIDATED CASH FLOW STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForDepreciationExpense", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Equity-settled share-based payments (Tables)", "menuCat": "Tables", "order": "60", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsTables", "shortName": "Equity-settled share-based payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutCapitalReservesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Capital reserves (Tables)", "menuCat": "Tables", "order": "61", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesTables", "shortName": "Capital reserves (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "sln:DisclosureOfDetailedInformationAboutCapitalReservesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Financial instruments and risk management (Tables)", "menuCat": "Tables", "order": "62", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables", "shortName": "Financial instruments and risk management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Notes to the cash flow statement (Tables)", "menuCat": "Tables", "order": "63", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementTables", "shortName": "Notes to the cash flow statement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Principal Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "64", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "shortName": "Principal Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "sln:DescriptionOfAccountingPolicyForGoingConcernTextBlock", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-5", "lang": null, "name": "sln:CashAndCashEquivalentsAndUSTreasuryBills", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_a3f993b6-ac4f-4781-bffe-6d3584d35d8b", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Revenue - Additional Information (Details)", "menuCat": "Details", "order": "65", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_a3f993b6-ac4f-4781-bffe-6d3584d35d8b", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "sln:RevenueFromContractsWithCustomersResearchCollaboration", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Revenue - Summary of Disaggregation of Revenue from Contracts with Customers (Details)", "menuCat": "Details", "order": "66", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "shortName": "Revenue - Summary of Disaggregation of Revenue from Contracts with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_f7a8076d-c870-4ff3-9ee8-8d60d7f84df1", "decimals": "-3", "lang": null, "name": "sln:RevenueFromContractsWithCustomersResearchCollaboration", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Segment Reporting - Additional Information (Details)", "menuCat": "Details", "order": "67", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingAdditionalInformationDetails", "shortName": "Segment Reporting - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Segment Reporting - Summary of the Analysis of Group's Assets and Revenues by Location (Details)", "menuCat": "Details", "order": "68", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails", "shortName": "Segment Reporting - Summary of the Analysis of Group's Assets and Revenues by Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_0a101b2c-77eb-41cc-be19-c8943a45a59c", "decimals": "-3", "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:SummaryOfOperatingLossExplanatory", "div", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DepreciationPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Operating Loss - Summary of Operating Loss (Details)", "menuCat": "Details", "order": "69", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails", "shortName": "Operating Loss - Summary of Operating Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:SummaryOfOperatingLossExplanatory", "div", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_a3f993b6-ac4f-4781-bffe-6d3584d35d8b", "decimals": "-3", "lang": null, "name": "ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - General information", "menuCat": "Notes", "order": "7", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGeneralInformation", "shortName": "General information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory", "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Directors and Staff Costs - Summary of Staff Costs, Including Directors' Remuneration (Details)", "menuCat": "Details", "order": "70", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails", "shortName": "Directors and Staff Costs - Summary of Staff Costs, Including Directors' Remuneration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory", "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:AverageNumberOfEmployeesInResearchAndDevelopmentAndRelatedSupportServices", "reportCount": 1, "unique": true, "unitRef": "U_Employee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Directors and Staff Costs - Summary of Total Average Number of Employees (Details)", "menuCat": "Details", "order": "71", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails", "shortName": "Directors and Staff Costs - Summary of Total Average Number of Employees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "sln:DisclosureOfDirectorsAndStaffCostsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:AverageNumberOfEmployeesInResearchAndDevelopmentAndRelatedSupportServices", "reportCount": 1, "unique": true, "unitRef": "U_Employee", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Other Losses - Summary of Other Losses (Detail)", "menuCat": "Details", "order": "72", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail", "shortName": "Other Losses - Summary of Other Losses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfSummaryOfOtherLossesGainsExplanatory", "div", "sln:DisclosureOfOtherLossesGainsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_a3f993b6-ac4f-4781-bffe-6d3584d35d8b", "decimals": "-3", "lang": null, "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Finance and Other Expenses - Summary of Finance and Other Expenses (Details)", "menuCat": "Details", "order": "73", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails", "shortName": "Finance and Other Expenses - Summary of Finance and Other Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:SummaryOfFinanceAndOtherIncomeExplanatory", "div", "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestRevenueExpense", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Finance and Other Income - Summary of Finance and Other Income (Details)", "menuCat": "Details", "order": "74", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails", "shortName": "Finance and Other Income - Summary of Finance and Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:SummaryOfFinanceAndOtherIncomeExplanatory", "div", "sln:DisclosureOfFinanceAndOtherIncomeExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestRevenueExpense", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfComponentsOfTaxationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Taxation - Additional Information (Details)", "menuCat": "Details", "order": "75", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails", "shortName": "Taxation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "lang": null, "name": "ifrs-full:DeferredTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfComponentsOfTaxationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Taxation - Components of Taxation (Details)", "menuCat": "Details", "order": "76", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails", "shortName": "Taxation - Components of Taxation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfComponentsOfTaxationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Taxation - Summary of Reconciliation of Tax Credit at Standard Rate of U.K. Corporation Tax to Current Tax Credit (Details)", "menuCat": "Details", "order": "77", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails", "shortName": "Taxation - Summary of Reconciliation of Tax Credit at Standard Rate of U.K. Corporation Tax to Current Tax Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "lang": null, "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Taxation - Summary of Reconciliation of Current Tax Credit at Standard Rate of UK Corporation Tax to Current Tax Credit (Parenthetical) (Details)", "menuCat": "Details", "order": "78", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfCurrentTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditParentheticalDetails", "shortName": "Taxation - Summary of Reconciliation of Current Tax Credit at Standard Rate of UK Corporation Tax to Current Tax Credit (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Loss Per Ordinary Equity Share (Basic and Diluted) - Additional Information (Details)", "menuCat": "Details", "order": "79", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLossPerOrdinaryEquityShareBasicAndDilutedAdditionalInformationDetails", "shortName": "Loss Per Ordinary Equity Share (Basic and Diluted) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Principal accounting policies", "menuCat": "Notes", "order": "8", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPolicies", "shortName": "Principal accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "80", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c6fe86b4-3865-4346-9354-be40d5faa36c", "decimals": "-3", "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Goodwill", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Goodwill - Summary of Reconciliation of Goodwill (Details)", "menuCat": "Details", "order": "81", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillSummaryOfReconciliationOfGoodwillDetails", "shortName": "Goodwill - Summary of Reconciliation of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory", "div", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_d896965b-f036-4778-960c-af33a3ecd3f1", "decimals": "-3", "lang": null, "name": "ifrs-full:Goodwill", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:NumberOfOperatingSegment", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Goodwill - Additional Information (Details)", "menuCat": "Details", "order": "82", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails", "shortName": "Goodwill - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "INF", "first": true, "lang": null, "name": "sln:NumberOfOperatingSegment", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:SummaryOfOperatingLossExplanatory", "div", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Other Intangible Assets - Summary of Other Intangible Assets (Details)", "menuCat": "Details", "order": "83", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "shortName": "Other Intangible Assets - Summary of Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_9fbaee77-45bd-4d2b-bc21-bebbd5178f1b", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Other Intangible Assets - Additional Information (Details)", "menuCat": "Details", "order": "84", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "shortName": "Other Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "85", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails", "shortName": "Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_6024feba-6a34-4478-b069-5ef9347543de", "decimals": null, "first": true, "lang": "en-US", "name": "sln:MaturityOfShortTermBankDeposits", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Cash and cash equivalents - Additional Information (Details)", "menuCat": "Details", "order": "86", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "shortName": "Cash and cash equivalents - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_6024feba-6a34-4478-b069-5ef9347543de", "decimals": null, "first": true, "lang": "en-US", "name": "sln:MaturityOfShortTermBankDeposits", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_6024feba-6a34-4478-b069-5ef9347543de", "decimals": "-4", "first": true, "lang": null, "name": "ifrs-full:GainLossOnDesignationOfFinancialInstrumentAsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Derivative Financial Instruments (Additional Information) (Details)", "menuCat": "Details", "order": "87", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails", "shortName": "Derivative Financial Instruments (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_6024feba-6a34-4478-b069-5ef9347543de", "decimals": "-4", "first": true, "lang": null, "name": "ifrs-full:GainLossOnDesignationOfFinancialInstrumentAsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentFinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Financial Assets at Amortized Cost - Additional Information (Details)", "menuCat": "Details", "order": "88", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "shortName": "Financial Assets at Amortized Cost - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "sln:DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_0ae667a2-c40d-4add-a458-db78a1bff992", "decimals": "-5", "lang": null, "name": "ifrs-full:CurrentFinancialAssetsAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentFinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Financial Assets at Amortized Cost - Summary of Financial Assets at Amortized Cost (Details)", "menuCat": "Details", "order": "89", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "shortName": "Financial Assets at Amortized Cost - Summary of Financial Assets at Amortized Cost (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Revenue", "menuCat": "Notes", "order": "9", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory", "div", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Other current assets - Summary of Other Current Assets (Details)", "menuCat": "Details", "order": "90", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails", "shortName": "Other current assets - Summary of Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory", "div", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationOfTradeReceivablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100920 - Disclosure - Trade receivables - Summary of Trade Receivables (Details)", "menuCat": "Details", "order": "91", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails", "shortName": "Trade receivables - Summary of Trade Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfDetailedInformationOfTradeReceivablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:InterestReceivable", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Trade receivables - Additional Information (Details)", "menuCat": "Details", "order": "92", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesAdditionalInformationDetails", "shortName": "Trade receivables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:InterestReceivable", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Trade and Other Payables - Summary of Trade and Other Payables (Details)", "menuCat": "Details", "order": "93", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails", "shortName": "Trade and Other Payables - Summary of Trade and Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentLeaseLiabilities", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Lease liability - Summary of Lease Liability (Details)", "menuCat": "Details", "order": "94", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilitySummaryOfLeaseLiabilityDetails", "shortName": "Lease liability - Summary of Lease Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:ScheduleOfLeaseLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-5", "first": true, "lang": null, "name": "sln:RepaymentOfPrincipalPortionOfLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Lease liability - Additional Information (Details)", "menuCat": "Details", "order": "95", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails", "shortName": "Lease liability - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-5", "first": true, "lang": null, "name": "sln:RepaymentOfPrincipalPortionOfLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentContractLiabilities", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)", "menuCat": "Details", "order": "96", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails", "shortName": "Contract Liabilities - Schedule of Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R97": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfContractLiabilitiesTableTextBlock", "div", "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_72662f15-002e-4f2f-ae67-62956964098e", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Contract Liabilities - Schedule of Change in Contract Liabilities (Details)", "menuCat": "Details", "order": "97", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails", "shortName": "Contract Liabilities - Schedule of Change in Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfContractLiabilitiesTableTextBlock", "div", "ifrs-full:DisclosureOfInvestmentContractsLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "-3", "lang": null, "name": "sln:ContractLiabilitiesAdditionsDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "sln:UnrecognizedDeferredTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Deferred tax - Summary of Unrecognized Deferred Tax Assets (Details)", "menuCat": "Details", "order": "98", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails", "shortName": "Deferred tax - Summary of Unrecognized Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "sln:DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_c9a9248d-b405-4447-a077-04caa708f329", "decimals": "-3", "first": true, "lang": null, "name": "sln:UnrecognizedDeferredTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "U_GBP", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Deferred tax - Additional Information (Details)", "menuCat": "Details", "order": "99", "role": "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails", "shortName": "Deferred tax - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "body", "html" ], "baseRef": "sln-20221231.htm", "contextRef": "C_e1e5f4fd-8cd7-4732-bcfb-36d1c5fec082", "decimals": "2", "lang": null, "name": "sln:FutureTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } } }, "segmentCount": 99, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany", "verboseLabel": "Berlin, Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "U.K." } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.A.", "verboseLabel": "Hoboken, U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "U.S. Dollar" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "Amortization charges" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "auth_ref": [ "r201" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails": { "order": 0.0, "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 3.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods." } }, "en-us": { "role": { "label": "Adjustments for current tax of prior periods", "negatedLabel": "Adjustment in respect of prior year", "negatedTerseLabel": "Changes in estimate related to prior years", "terseLabel": "Changes in estimate related to prior years" } } }, "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other current assets", "terseLabel": "Increase in other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "(Increase)/decrease in trade and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationExpense": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation charges" } } }, "localname": "AdjustmentsForDepreciationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r282" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance costs", "terseLabel": "Finance and other expenses" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income", "negatedLabel": "Finance and other income" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } }, "en-us": { "role": { "label": "Adjustments for gain (loss) on disposals, property, plant and equipment", "negatedLabel": "(Gain) on disposal of property, plant and equipment" } } }, "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r283" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "Increase in trade and other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r281" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Charge for the year in respect of share-based payments" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r17", "r114", "r120", "r121", "r142", "r176", "r177", "r179", "r185", "r205", "r232", "r235" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]", "terseLabel": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "negatedLabel": "Amortisation, intangible assets other than goodwill", "terseLabel": "Amortization of intangibles" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r55", "r58" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Amounts paid, related party transactions" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "U.K. corporation tax rate", "verboseLabel": "Corporation tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfCurrentTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditParentheticalDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_AuditorsRemunerationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Auditor's remuneration [abstract]", "terseLabel": "Fees payable to the Company's auditors for the audit of the Company and the consolidation:" } } }, "localname": "AuditorsRemunerationAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AuditorsRemunerationForAuditServices": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services." } }, "en-us": { "role": { "label": "Auditor's remuneration for audit services", "terseLabel": "- audit fees" } } }, "localname": "AuditorsRemunerationForAuditServices", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AuditorsRemunerationForOtherServices": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Auditor's remuneration for other services", "terseLabel": "- other assurance services" } } }, "localname": "AuditorsRemunerationForOtherServices", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r269" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average currency conversion rate per US Dollar" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_AverageNumberOfEmployees": { "auth_ref": [ "r269" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } }, "en-us": { "role": { "label": "Average number of employees", "totalLabel": "Total average number of employees" } } }, "localname": "AverageNumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r109", "r134", "r179", "r220", "r221", "r286" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom Of Range [Member]", "verboseLabel": "Bottom of Range" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitments": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } }, "en-us": { "role": { "label": "Capital commitments", "terseLabel": "Capital commitments", "totalLabel": "Total capital commitments" } } }, "localname": "CapitalCommitments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalRedemptionReserveMember": { "auth_ref": [ "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing the reserve for the redemption of the entity's own shares." } }, "en-us": { "role": { "label": "Capital redemption reserve [member]", "terseLabel": "Capital Redemption Reserve" } } }, "localname": "CapitalRedemptionReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalReserve": { "auth_ref": [ "r272" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the capital reserves." } }, "en-us": { "role": { "label": "Capital reserve", "terseLabel": "Capital reserves" } } }, "localname": "CapitalReserve", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalReserveMember": { "auth_ref": [ "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } }, "en-us": { "role": { "label": "Capital reserve [member]", "terseLabel": "Capital Reserves" } } }, "localname": "CapitalReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r44", "r49", "r67", "r71", "r75", "r76", "r77", "r78", "r79", "r139", "r150", "r151", "r289", "r290" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r49", "r71", "r75", "r77", "r78", "r139", "r150", "r151", "r247", "r252" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r284" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails": { "order": 0.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and in hand", "totalLabel": "Total cash" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r12", "r85", "r104" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at start of year", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r80", "r86" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "netLabel": "Net cash flows from (used in) financing activities", "totalLabel": "Net cash inflow from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flow from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r80", "r86" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "netLabel": "Net cash flows from (used in) investing activities", "totalLabel": "Net cash (outflow)/inflow from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flow from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r80", "r86" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "netLabel": "Net cash flows from (used in) operating activities", "totalLabel": "Net cash (outflow)/inflow from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flow from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r212", "r216" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations", "netLabel": "Net cash flows from (used in) operations", "totalLabel": "Cash generated/(spent) on operations" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInFairValueOfCreditDerivativeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in fair value of credit derivative [abstract]" } } }, "localname": "ChangesInFairValueOfCreditDerivativeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "This member stands for changes in tax rates or tax laws enacted or announced." } }, "en-us": { "role": { "label": "Changes in tax rates or tax laws enacted or announced [member]", "terseLabel": "Changes in Tax Rates" } } }, "localname": "ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Classes of employee benefits expense [abstract]" } } }, "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r157", "r158", "r175", "r186", "r187", "r188" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r150", "r152", "r154", "r155" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]", "terseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r150", "r152", "r154", "r155" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]", "terseLabel": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r157", "r158", "r175", "r187" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial liabilities [axis]", "terseLabel": "Classes of financial liabilities [axis]" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of ordinary shares [axis]", "terseLabel": "Classes of ordinary shares [axis]" } } }, "localname": "ClassesOfOrdinarySharesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Items that may subsequently be reclassified to profit or loss:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Other comprehensive expense, net of tax:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r2", "r28", "r94", "r96", "r101", "r219" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive expense for the year" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractDurationAxis": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Contract duration [axis]", "terseLabel": "Contract duration [axis]" } } }, "localname": "ContractDurationAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ContractDurationMember": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for all durations of contracts with customers. It also represents the standard value for the 'Contract duration' axis if no other member is used." } }, "en-us": { "role": { "label": "Contract duration [member]", "terseLabel": "Contract duration [member]" } } }, "localname": "ContractDurationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r110", "r113" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Upfront payment", "periodEndLabel": "Contract liabilities, Ending balance", "periodStartLabel": "Contract liabilities, Beginning balance", "terseLabel": "Upfront payments received", "totalLabel": "Total contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract liabilities [abstract]" } } }, "localname": "ContractLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r0", "r34" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales", "negatedLabel": "Cost of sales" } } }, "localname": "CostOfSales", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]", "terseLabel": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]", "terseLabel": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r163", "r180", "r181", "r182", "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Currency Risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r272" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Current accrued expenses and other current liabilities", "terseLabel": "Accruals and other payables" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r18", "r97", "r219" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails": { "order": 0.0, "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "negatedLabel": "Contract liabilities", "terseLabel": "Current", "totalLabel": "Total current contract liabilities" } } }, "localname": "CurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentDerivativeFinancialAssets": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]" } }, "en-us": { "role": { "label": "Current derivative financial assets", "terseLabel": "Derivative financial instrument" } } }, "localname": "CurrentDerivativeFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDerivativeFinancialInstrumentsSummaryOfDerivativesCarriedAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssetsAtAmortisedCost": { "auth_ref": [ "r160" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Current financial assets at amortised cost", "terseLabel": "Total financial assets at amortized cost - current", "verboseLabel": "Current financial assets at amortized cost" } } }, "localname": "CurrentFinancialAssetsAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilitySummaryOfLeaseLiabilityDetails": { "order": 0.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "negatedLabel": "Lease liability", "terseLabel": "Lease liability" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilitySummaryOfLeaseLiabilityDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r19", "r99", "r219" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "negatedLabel": "Current liabilities", "negatedTotalLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "auth_ref": [ "r274" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } }, "en-us": { "role": { "label": "Current payables on social security and taxes other than income tax", "terseLabel": "Social security and other taxes" } } }, "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepayments": { "auth_ref": [ "r195" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } }, "en-us": { "role": { "label": "Current prepayments", "terseLabel": "Prepayments", "totalLabel": "Total current prepayments" } } }, "localname": "CurrentPrepayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxAssetsCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } }, "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "R&D tax credit receivable" } } }, "localname": "CurrentTaxAssetsCurrent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncome": { "auth_ref": [ "r200" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Current tax expense (income)", "negatedLabel": "Current tax credit", "terseLabel": "Current Year" } } }, "localname": "CurrentTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "auth_ref": [ "r277" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } }, "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current tax credit", "totalLabel": "Total current tax" } } }, "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods [abstract]", "terseLabel": "Current Tax Expense" } } }, "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r193", "r195" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "CurrentTradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxReceivables": { "auth_ref": [ "r273" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivable" } } }, "localname": "CurrentValueAddedTaxReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets and liabilities [abstract]" } } }, "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxExpenseIncome": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred tax expense (income)", "terseLabel": "Deferred tax charge" } } }, "localname": "DeferredTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) [abstract]", "terseLabel": "Deferred Tax Expense" } } }, "localname": "DeferredTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "terseLabel": "Deferred tax expense (income) recognized in profit or loss" } } }, "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences", "terseLabel": "Origination and reversal of temporary differences" } } }, "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax expense or income relating to tax rate changes or the imposition of new taxes. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) relating to tax rate changes or imposition of new taxes", "terseLabel": "Change in tax rate" } } }, "localname": "DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r47", "r51" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "negatedLabel": "Depreciation, property, plant and equipment", "terseLabel": "Charge for the year", "verboseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for business combinations [text block]", "terseLabel": "Business combinations" } } }, "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Defined contribution pension funds" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency translation" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for goodwill [text block]", "terseLabel": "Goodwill" } } }, "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of assets.\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of assets." } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of assets [text block]", "terseLabel": "Impairment testing of goodwill, other intangible assets and property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Taxation" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Other intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Equity" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leased assets" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue recognition" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment reporting" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r287", "r288" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility", "verboseLabel": "Volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Option life (years)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of useful life, intangible assets other than goodwill", "terseLabel": "Description of estimated useful life, intangible assets" } } }, "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure of cash flow statement [text block]", "terseLabel": "Notes to the cash flow statement" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for changes in accounting policies, accounting estimates and errors." } }, "en-us": { "role": { "label": "Disclosure of changes in accounting policies, accounting estimates and errors [text block]", "terseLabel": "Principal accounting policies" } } }, "localname": "DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]", "terseLabel": "Disclosure Of Classes Of Share Capital [Table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "terseLabel": "Capital commitments and contingent liabilities" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalCommitmentsAndContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of credit risk exposure [abstract]" } } }, "localname": "DisclosureOfCreditRiskExposureAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureExplanatory": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity\u2019s financial assets and commitments to extend credit." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [text block]", "terseLabel": "Summary of Credit Quality of Financial Assets" } } }, "localname": "DisclosureOfCreditRiskExposureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [line items]", "terseLabel": "Disclosure Of Credit Risk Exposure [Line Items]" } } }, "localname": "DisclosureOfCreditRiskExposureLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [table]", "terseLabel": "Disclosure Of Credit Risk Exposure [Table]" } } }, "localname": "DisclosureOfCreditRiskExposureTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "terseLabel": "Deferred tax" } } }, "localname": "DisclosureOfDeferredTaxesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Disclosure of derivative financial instruments [text block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about hedged items [abstract]" } } }, "localname": "DisclosureOfDetailedInformationAboutHedgedItemsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about hedged items [line items]", "terseLabel": "Disclosure Of Detailed Information About Hedged Items [Line Items]" } } }, "localname": "DisclosureOfDetailedInformationAboutHedgedItemsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of hedged items." } }, "en-us": { "role": { "label": "Disclosure of detailed information about hedged items [table]", "terseLabel": "Disclosure Of Detailed Information About Hedged Items [Table]" } } }, "localname": "DisclosureOfDetailedInformationAboutHedgedItemsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Summary of other intangible assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "terseLabel": "Summary of Disaggregation of Revenue from Contracts with Customers" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]", "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r63" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Loss per ordinary equity share (basic and diluted)" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLossPerOrdinaryEquityShareBasicAndDiluted" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Post Balance Sheet Events" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePostBalanceSheetEvents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Summary of Derivatives Carried at Fair Value" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance cost. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Disclosure of finance cost [text block]", "terseLabel": "Finance and other expenses" } } }, "localname": "DisclosureOfFinanceCostExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [abstract]" } } }, "localname": "DisclosureOfFinancialAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Disclosure of financial assets [text block]", "terseLabel": "Summary of Financial Assets by Category" } } }, "localname": "DisclosureOfFinancialAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial assets [line items]", "terseLabel": "Disclosure of Financial Assets [Line Items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure of financial assets [table]", "terseLabel": "Disclosure Of Financial Assets [Table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial instruments and risk management" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Disclosure Of Financial Instruments [Line Items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r146", "r152", "r159" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]", "terseLabel": "Disclosure Of Financial Instruments [Table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [abstract]" } } }, "localname": "DisclosureOfFinancialLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [text block]", "terseLabel": "Summary of Financial Liabilities by Category" } } }, "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [line items]", "terseLabel": "Disclosure Of Financial Liabilities [Line Items]" } } }, "localname": "DisclosureOfFinancialLiabilitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [table]", "terseLabel": "Disclosure Of Financial Liabilities [Table]" } } }, "localname": "DisclosureOfFinancialLiabilitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "General information" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGeneralInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The disclosure of geographical information." } }, "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Summary of the Analysis of Group's Assets and Revenues by Location" } } }, "localname": "DisclosureOfGeographicalAreasExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGoodwillExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Disclosure of goodwill [text block]", "terseLabel": "Goodwill" } } }, "localname": "DisclosureOfGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwill" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r42" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Taxation" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Summery of Fair Value of Options Granted, Calculated Using Binomial or Monte Carlo Model and Inputs Into the Model" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about employees." } }, "en-us": { "role": { "label": "Disclosure of information about employees [text block]", "terseLabel": "Summary of Total Average Number of Employees" } } }, "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Other intangible assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Disclosure Of Intangible Assets [Line Items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]", "terseLabel": "Disclosure Of Intangible Assets [Table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInvestmentContractsLiabilitiesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of investment contracts liabilities. [Refer: Investment contracts liabilities]" } }, "en-us": { "role": { "label": "Disclosure of investment contracts liabilities [text block]", "terseLabel": "Contract liabilities" } } }, "localname": "DisclosureOfInvestmentContractsLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Disclosure of issued capital [text block]", "terseLabel": "Summary of details of shares issued" } } }, "localname": "DisclosureOfIssuedCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r122", "r123" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Lease liability" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiability" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Summary of Options" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]" } } }, "localname": "DisclosureOfOperatingSegmentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "auth_ref": [ "r167" ], "lang": { "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Disclosure of operating segments [text block]", "terseLabel": "Segment reporting" } } }, "localname": "DisclosureOfOperatingSegmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReporting" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of operating segments [line items]", "terseLabel": "Disclosure Of Operating Segments [Line Items]" } } }, "localname": "DisclosureOfOperatingSegmentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "auth_ref": [ "r167" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } }, "en-us": { "role": { "label": "Disclosure of operating segments [table]", "terseLabel": "Disclosure Of Operating Segments [Table]" } } }, "localname": "DisclosureOfOperatingSegmentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } }, "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Other current assets" } } }, "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]" } }, "en-us": { "role": { "label": "Disclosure of profit (loss) from operating activities [text block]", "terseLabel": "Operating loss" } } }, "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLoss" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Disclosure Of Property Plant And Equipment [Line Items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]", "terseLabel": "Disclosure Of Property Plant And Equipment [Table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } }, "en-us": { "role": { "label": "Disclosure of range of exercise prices of outstanding share options [text block]", "terseLabel": "Summary of options outstanding" } } }, "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in goodwill [abstract]" } } }, "localname": "DisclosureOfReconciliationOfChangesInGoodwillAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Disclosure of reconciliation of changes in goodwill [text block]", "terseLabel": "Summary of Reconciliation of Goodwill" } } }, "localname": "DisclosureOfReconciliationOfChangesInGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [abstract]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]", "terseLabel": "Summary of Changes in Liabilities Arising from Financing Activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]", "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [text block]", "terseLabel": "Capital reserves" } } }, "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReserves" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of reserves within equity [abstract]" } } }, "localname": "DisclosureOfReservesWithinEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [line items]", "terseLabel": "Disclosure Of Reserves Within Equity [Line Items]" } } }, "localname": "DisclosureOfReservesWithinEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityTable": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to reserves within equity." } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [table]", "terseLabel": "Disclosure Of Reserves Within Equity [Table]" } } }, "localname": "DisclosureOfReservesWithinEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r115", "r116" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue" } } }, "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Share capital" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapital" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Equity-settled share-based payments" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "terseLabel": "Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Trade and other payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Trade receivables" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Related party transactions" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Line Items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r82", "r83" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effect of exchange rate fluctuations on cash and cash equivalents held" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r34", "r190" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "negatedLabel": "Employee benefits expense", "totalLabel": "Total aggregate remuneration" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForExternalCreditGradesMember": { "auth_ref": [ "r189", "r230", "r237", "r245", "r248" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for external credit grades [member]", "terseLabel": "Entity's total for external credit grades [member]" } } }, "localname": "EntitysTotalForExternalCreditGradesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]", "terseLabel": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r15", "r21", "r93", "r95", "r106", "r107", "r108" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Total equity", "totalLabel": "Total shareholders equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Capital and reserves attributable to the owners of the parent" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The exercise price of outstanding share options." } }, "en-us": { "role": { "label": "Exercise price of outstanding share options", "terseLabel": "Option exercise price" } } }, "localname": "ExercisePriceOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Weighted average exercise price (pence)" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Expected dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseByNatureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses by nature [abstract]" } } }, "localname": "ExpenseByNatureAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r269" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Share-based payments charge" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExternalCreditGradesAxis": { "auth_ref": [ "r189", "r230", "r237", "r245", "r248" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "External credit grades [axis]", "terseLabel": "External credit grades [axis]" } } }, "localname": "ExternalCreditGradesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ExternalCreditGradesMember": { "auth_ref": [ "r189", "r230", "r237", "r245", "r248" ], "lang": { "en": { "role": { "documentation": "This member stands for credit grades that have been provided by external rating agencies." } }, "en-us": { "role": { "label": "External credit grades [member]", "terseLabel": "Credit Risk" } } }, "localname": "ExternalCreditGradesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r30" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Finance and other expenses", "totalLabel": "Total Finance and other expenses" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r276" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance and other income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r145", "r150", "r151", "r154", "r231" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails": { "order": 0.0, "parentTag": "sln_NetFinancialAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets", "periodEndLabel": "Financial assets at end of period", "periodStartLabel": "Financial assets at beginning of period", "terseLabel": "Financial assets", "totalLabel": "Total financial assets" } } }, "localname": "FinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCost": { "auth_ref": [ "r160" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets at amortised cost", "terseLabel": "Purchase of financial assets at amortized cost", "totalLabel": "Total financial assets at amortized cost" } } }, "localname": "FinancialAssetsAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r157", "r158", "r175", "r186", "r187", "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsTypeMember": { "auth_ref": [ "r161", "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated types of financial assets. It also represents the standard value for the 'Types of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, type [member]", "terseLabel": "Financial assets, type [member]" } } }, "localname": "FinancialAssetsTypeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember": { "auth_ref": [ "r88", "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial effect of changes in accounting policy." } }, "en-us": { "role": { "label": "Increase (decrease) due to changes in accounting policy [member]", "terseLabel": "Adjusted Balance" } } }, "localname": "FinancialEffectOfChangesInAccountingPolicyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r145" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails": { "order": 1.0, "parentTag": "sln_NetFinancialAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "negatedLabel": "Financial liabilities", "terseLabel": "Financial liabilities", "totalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r157", "r158", "r175", "r187" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, class [member]", "terseLabel": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FixedInterestRateMember": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Fixed interest rate [member]", "terseLabel": "Fixed Interest Rate" } } }, "localname": "FixedInterestRateMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignExchangeLoss": { "auth_ref": [ "r8", "r53" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange loss", "terseLabel": "Foreign exchange loss" } } }, "localname": "ForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainLossOnDesignationOfFinancialInstrumentAsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk": { "auth_ref": [ "r144" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gain (loss) recognised on designation of a financial instrument, or a proportion of it, as measured at fair value through profit or loss, because a credit derivative is used to manage the credit risk of that financial instrument. [Refer: Credit risk [member]; Derivatives [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Gain (loss) on designation of financial instrument as measured at fair value through profit or loss because credit derivative is used to manage credit risk", "terseLabel": "Gain on the derivative financial instrument" } } }, "localname": "GainLossOnDesignationOfFinancialInstrumentAsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r276" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail": { "order": 1.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Gains (losses) on change in fair value of derivatives", "netLabel": "Net gains (losses) on change in fair value of derivatives", "terseLabel": "Net fair value gain on derivative" } } }, "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Gains (losses) on disposals of property, plant and equipment", "netLabel": "Net gains (losses) on disposals of property, plant and equipment", "terseLabel": "(Gain)/loss on disposal of property, plant and equipment" } } }, "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r8", "r53" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail": { "order": 0.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "negatedLabel": "Net foreign exchange (gain)/loss", "netLabel": "Net foreign exchange gain (loss)", "terseLabel": "Net foreign exchange losses" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r269" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r173", "r204", "r223", "r243" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]", "terseLabel": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r173", "r204", "r223", "r243" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]", "terseLabel": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Goodwill": { "auth_ref": [ "r11", "r64", "r65", "r139" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at start of year", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillSummaryOfReconciliationOfGoodwillDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r44", "r67", "r76", "r79", "r139", "r151", "r154", "r231", "r289", "r290" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross carrying amount [member]", "terseLabel": "Cost" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossProfit": { "auth_ref": [ "r191" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } }, "en-us": { "role": { "label": "Gross profit", "netLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_HedgedItemsAxis": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Hedged items [axis]", "terseLabel": "Hedged items [axis]" } } }, "localname": "HedgedItemsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_HedgedItemsMember": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used." } }, "en-us": { "role": { "label": "Hedged items [member]", "terseLabel": "Hedged items [member]" } } }, "localname": "HedgedItemsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r31", "r37", "r38", "r39", "r59", "r105", "r166" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Taxation", "negatedTerseLabel": "Tax income (expense)", "negatedTotalLabel": "Taxation", "totalLabel": "Taxation" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/DisclosureTaxationComponentsOfTaxationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember": { "auth_ref": [ "r88", "r89" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial effect of changes in accounting policy required by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) due to changes in accounting policy required by IFRSs [member]", "terseLabel": "Adoption of IFRS 16" } } }, "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r85" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "(Decrease)/increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r269" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "terseLabel": "Shares issued during the year", "verboseLabel": "Costs capitalised in respect of issuance of shares during the period" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r267" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets", "weight": -1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Options exercised in the year", "verboseLabel": "On options exercised during the year" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "terseLabel": "Cash flows from financing activities : Repayments" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, goodwill", "terseLabel": "Translation adjustment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillSummaryOfReconciliationOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Translation adjustment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Translation adjustment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": { "auth_ref": [ "r6" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Increase through other contributions by owners, equity", "totalLabel": "Transactions with owners recognized directly in equity" } } }, "localname": "IncreaseDecreaseThroughOtherContributionsByOwners", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets": { "auth_ref": [ "r228", "r229", "r236" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in financial assets resulting from other movements. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Increase (decrease) through other movements, financial assets", "totalLabel": "Movement in the year" } } }, "localname": "IncreaseDecreaseThroughOtherMovementsFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r6" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Recognition of share-based payments" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r213", "r216" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase through new leases, liabilities arising from financing activities", "terseLabel": "Non-cash flows: New lease liabilities" } } }, "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InformationAboutNatureOfLesseesLeasingActivities": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "Information about the nature of the lessee's leasing activities." } }, "en-us": { "role": { "label": "Information about nature of lessee's leasing activities", "terseLabel": "Lease description" } } }, "localname": "InformationAboutNatureOfLesseesLeasingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r11", "r71" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r72", "r207", "r226" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r119" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Lease liability interest expense" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRateTypesMember": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Interest rate types [member]", "terseLabel": "Interest rate types [member]" } } }, "localname": "InterestRateTypesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestReceivable": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } }, "en-us": { "role": { "label": "Interest receivable", "terseLabel": "Interest on outstanding receivables" } } }, "localname": "InterestReceivable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRevenueExpense": { "auth_ref": [ "r167", "r170", "r276" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails": { "order": 0.0, "parentTag": "sln_FinanceAndOtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } }, "en-us": { "role": { "label": "Interest income (expense)", "terseLabel": "Bank interest receivable" } } }, "localname": "InterestRevenueExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r6" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets", "weight": -1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issuance and sale of securities", "terseLabel": "Proceeds from shares issued", "verboseLabel": "Shares issued" } } }, "localname": "IssueOfEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r196" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital", "totalLabel": "Total issued capital" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfShareCapitalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share Capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r120", "r121", "r185", "r232", "r238", "r269" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "Later than one year and not later than two years [member]", "terseLabel": "Due between 1 to 2 Years" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearMember": { "auth_ref": [ "r16", "r246", "r251" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year." } }, "en-us": { "role": { "label": "Later than one year [member]", "terseLabel": "More than One Year" } } }, "localname": "LaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": { "auth_ref": [ "r232", "r234", "r238", "r246", "r250" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than six months and not later than one year." } }, "en-us": { "role": { "label": "Later than six months and not later than one year [member]", "terseLabel": "Due in 6 to 12 Months" } } }, "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": { "auth_ref": [ "r232", "r233", "r238", "r246", "r249" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three months and not later than six months." } }, "en-us": { "role": { "label": "Later than three months and not later than six months [member]", "terseLabel": "Due within 6 Months" } } }, "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilitySummaryOfLeaseLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "totalLabel": "Total lease liability" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilitySummaryOfLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r214", "r217" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease Liability" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities", "periodEndLabel": "December31, 2021", "periodStartLabel": "January 1, 2021" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]", "terseLabel": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities [member]", "terseLabel": "Liabilities arising from financing activities [member]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureNotesToCashFlowStatementSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermContractsMember": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for long-term contracts with customers." } }, "en-us": { "role": { "label": "Long-term contracts [member]", "terseLabel": "Non-current" } } }, "localname": "LongtermContractsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Major Ordinary Share Transactions" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r17", "r114", "r120", "r121", "r142", "r156", "r176", "r177", "r179", "r185", "r205", "r232" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]", "terseLabel": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MergerReserveMember": { "auth_ref": [ "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity that may result in relation to a business combination outside the scope of IFRS 3." } }, "en-us": { "role": { "label": "Merger reserve [member]", "terseLabel": "Merger Reserve" } } }, "localname": "MergerReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MiscellaneousCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Miscellaneous current assets [abstract]", "terseLabel": "Miscellaneous Current Assets [Abstract]" } } }, "localname": "MiscellaneousCurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Miscellaneous other comprehensive income [abstract]" } } }, "localname": "MiscellaneousOtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r218", "r269" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Assets (liabilities)", "netLabel": "Net assets (liabilities)", "totalLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r271", "r279" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails": { "order": 1.0, "parentTag": "sln_FinanceAndOtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Net foreign exchange gains" } } }, "localname": "NetForeignExchangeGain", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r271", "r279" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "terseLabel": "Net foreign exchange losses" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesSummaryOfFinanceAndOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]", "terseLabel": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r18", "r98", "r219" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "terseLabel": "Non-current assets", "totalLabel": "Non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentContractLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails": { "order": 1.0, "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Non-current contract liabilities", "negatedLabel": "Contract liabilities", "terseLabel": "Non-current", "totalLabel": "Total non-current contract liabilities" } } }, "localname": "NoncurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost": { "auth_ref": [ "r160" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails": { "order": 0.0, "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Non-current financial assets at amortised cost", "terseLabel": "Financial assets at amortized cost" } } }, "localname": "NoncurrentFinancialAssetsAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r19", "r100", "r219" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "negatedTotalLabel": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_NumberAndAverageNumberOfEmployeesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number and average number of employees [abstract]" } } }, "localname": "NumberAndAverageNumberOfEmployeesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r125", "r130", "r134" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "At December 31, 2022", "periodStartLabel": "At January 1, 2022", "terseLabel": "Options outstanding" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable at the year-end" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedLabel": "Options exercised", "terseLabel": "Options exercised" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options expired in share-based payment arrangement", "terseLabel": "Options expired" } } }, "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Options forfeited" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Options granted", "verboseLabel": "Options granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r267" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "periodEndLabel": "Number of shares in issue, ending balance", "periodStartLabel": "Number of shares in issue, beginning balance", "terseLabel": "Number of shares in issue", "totalLabel": "Total number of shares issued", "verboseLabel": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r60", "r275" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary shares [member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r5", "r27", "r32", "r103" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Total other comprehensive income/(expense) for the year" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive (expense) income" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r20", "r32" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 0.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Foreign exchange differences arising on consolidation of foreign operations", "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r272" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Total other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsSummaryOfOtherCurrentAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherGainsLosses": { "auth_ref": [ "r265", "r266" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other gains (losses)", "terseLabel": "Other losses - net", "totalLabel": "Total Other losses" } } }, "localname": "OtherGainsLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesSummaryOfOtherLossesDetail", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIntangibleAssets": { "auth_ref": [ "r280" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Other intangible assets", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r7", "r24" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Other reserves [member]" } } }, "localname": "OtherReservesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value", "verboseLabel": "Price per share" } } }, "localname": "ParValuePerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r211" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities", "negatedTerseLabel": "Payments of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r210" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from issue of share capital" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r209" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r171", "r222" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]", "terseLabel": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r171", "r222" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products and services [member]", "terseLabel": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r4", "r26", "r81", "r94", "r96", "r167", "r169", "r219", "r241", "r244" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "negatedLabel": "Loss for the year after taxation", "terseLabel": "Loss for the year after taxation", "totalLabel": "Loss for the year after taxation" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "negatedLabel": "Net loss used in the calculation of loss per share", "totalLabel": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share" } } }, "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLossPerOrdinaryEquityShareBasicAndDilutedAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r140", "r190", "r191", "r239", "r240" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Loss before tax", "totalLabel": "Loss for the year before taxation" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r206", "r276" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r10", "r49" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Property, plant and equipment", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r50", "r207", "r226" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r208" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Purchase of intangible assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r208" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property, plant and equipment", "negatedTerseLabel": "Purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r109", "r134", "r179", "r220", "r221", "r286" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]", "terseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r109", "r134", "r179", "r220", "r221", "r286" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]", "terseLabel": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]", "terseLabel": "Ranges of exercise prices for outstanding share options [axis]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]" } }, "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [member]", "terseLabel": "Ranges of exercise prices for outstanding share options [member]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "auth_ref": [ "r110", "r113" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } }, "en-us": { "role": { "label": "Receivables from contracts with customers", "periodEndLabel": "Receivables from contracts with customers at end of period", "periodStartLabel": "Receivables from contracts with customers at beginning of period", "terseLabel": "Milestones to be received in next 12 months", "totalLabel": "Total receivables from contracts with customers", "verboseLabel": "Additional development, regulatory and commercial milestone payments" } } }, "localname": "ReceivablesFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]" } } }, "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r73" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r54" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r54", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation Reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve of share-based payments [member]", "terseLabel": "Share-based Payment Reserve" } } }, "localname": "ReserveOfSharebasedPaymentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReservesWithinEquityAxis": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Reserves within equity [axis]", "terseLabel": "Reserves within equity [axis]" } } }, "localname": "ReservesWithinEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RestatedMember": { "auth_ref": [ "r3", "r88", "r90", "r91", "r178", "r270" ], "lang": { "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } }, "en-us": { "role": { "label": "Currently stated [member]", "terseLabel": "Currently stated [member]" } } }, "localname": "RestatedMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r196", "r197" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "negatedLabel": "Accumulated losses", "terseLabel": "Accumulated losses", "totalLabel": "Total retained earnings" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r7", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated Losses" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "auth_ref": [ "r3", "r88", "r90", "r91" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]", "terseLabel": "Retrospective application and retrospective restatement [axis]" } } }, "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r29", "r102", "r140", "r165", "r168", "r171", "r172", "r174", "r190", "r191", "r219" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue", "totalLabel": "Total revenue" } } }, "localname": "Revenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [abstract]" } } }, "localname": "RevenueAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r111", "r112" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue", "totalLabel": "Total revenue from contracts with customers" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromRoyalties": { "auth_ref": [ "r269" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails": { "order": 0.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails": { "order": 1.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from royalties." } }, "en-us": { "role": { "label": "Royalty income", "terseLabel": "Royalties" } } }, "localname": "RevenueFromRoyalties", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsMember": { "auth_ref": [ "r117" ], "lang": { "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right-of-use assets [member]", "terseLabel": "Right-of-use Assets" } } }, "localname": "RightofuseAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Share Premium Account" } } }, "localname": "SharePremiumMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermContractsMember": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for short-term contracts with customers." } }, "en-us": { "role": { "label": "Short-term contracts [member]", "terseLabel": "Current" } } }, "localname": "ShorttermContractsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r284" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails": { "order": 2.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short term bank deposits" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SocialSecurityContributions": { "auth_ref": [ "r278" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Social security contributions", "terseLabel": "Social security costs" } } }, "localname": "SocialSecurityContributions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Statement Of Changes In Equity [Line Items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]", "terseLabel": "Statement Of Changes In Equity [Table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r38" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 1.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedLabel": "Effect of overseas tax rate" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r38" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 0.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Tax credit at the standard rate of U.K. corporation tax of 19% (2020: 19% ; 2019: 19%)" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r109", "r134", "r179", "r220", "r221", "r286" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of Range", "verboseLabel": "Top of Range" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r13" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "negatedLabel": "Trade and other payables", "totalLabel": "Total trade and other current payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other current payables [abstract]" } } }, "localname": "TradeAndOtherCurrentPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r194", "r274" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails": { "order": 0.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayables": { "auth_ref": [ "r13" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } }, "en-us": { "role": { "label": "Trade and other payables", "totalLabel": "Total trade and other payables" } } }, "localname": "TradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "localname": "TradeAndOtherReceivablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeReceivables": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } }, "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "TradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r149", "r153", "r231", "r269" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Trade Receivables" } } }, "localname": "TradeReceivablesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfContractsAxis": { "auth_ref": [ "r224", "r242" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of contracts [axis]", "terseLabel": "Types of contracts [axis]" } } }, "localname": "TypesOfContractsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfContractsMember": { "auth_ref": [ "r224", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of contracts [member]", "terseLabel": "Types of contracts [member]" } } }, "localname": "TypesOfContractsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfFinancialAssetsAxis": { "auth_ref": [ "r161", "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of financial assets [axis]", "terseLabel": "Types of financial assets [axis]" } } }, "localname": "TypesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfInterestRatesAxis": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of interest rates [axis]", "terseLabel": "Types of interest rates [axis]" } } }, "localname": "TypesOfInterestRatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r141", "r147", "r148", "r180", "r181", "r182", "r184" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r141", "r147", "r148", "r180", "r181", "r182", "r184" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of undiscounted finance lease payments to be received. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Undiscounted finance lease payments to be received", "terseLabel": "Lease liability due" } } }, "localname": "UndiscountedFinanceLeasePaymentsToBeReceived", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Intangible assets with indefinite useful life" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Estimated useful economic life of property, plant and equipment" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r278" ], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails": { "order": 0.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages and salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable at the year-end, Weighted Average Exercise Price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Exercised during the year, Weighted Average Exercise Price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Lapsed or forfeited during the year, Weighted Average Exercise Price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Granted during the year, Weighted Average Exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r125", "r130" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding balance, Weighted Average Exercise Price", "periodStartLabel": "Outstanding balance, Weighted Average Exercise price", "terseLabel": "Weighted average Exercise price (\u00a3)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average share price" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average ordinary shares issued" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLossPerOrdinaryEquityShareBasicAndDilutedAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sln_AccretionOnUSTreasuryBills": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails": { "order": 2.0, "parentTag": "sln_FinanceAndOtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion on U.S treasury bills.", "label": "Accretion On U.S Treasury Bills", "terseLabel": "Accretion on U.S Treasury Bills" } } }, "localname": "AccretionOnUSTreasuryBills", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "sln_AccumulatedDepreciationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated depreciation.", "label": "Accumulated Depreciation [Member]", "terseLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "sln_AdjustmentForRevaluationOfTradeAndOtherReceivablesRelatedToContractLiabilities": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment for revaluation of trade and other receivables related to contract liabilities.", "label": "Adjustment For Revaluation Of Trade And Other Receivables Related To Contract Liabilities", "negatedLabel": "Revaluation of trade and other receivables related to contract liabilities" } } }, "localname": "AdjustmentForRevaluationOfTradeAndOtherReceivablesRelatedToContractLiabilities", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_AdjustmentsForDecreaseIncreaseInContractLiabilities": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in contract liabilities.", "label": "Adjustments For Decrease Increase In Contract Liabilities", "terseLabel": "(Decrease)/increase in contract liabilities" } } }, "localname": "AdjustmentsForDecreaseIncreaseInContractLiabilities", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_AdjustmentsForDecreaseIncreaseInDerivativeFinancialInstruments": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in derivative financial instruments.", "label": "Adjustments For Decrease Increase In Derivative Financial Instruments", "terseLabel": "Decrease in derivative financial instrument" } } }, "localname": "AdjustmentsForDecreaseIncreaseInDerivativeFinancialInstruments", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_AdjustmentsForGainLossOnDerivativeFinancialInstrument": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments For gain loss on derivative financial instrument.", "label": "Adjustments For Gain Loss On Derivative Financial Instrument", "terseLabel": "(Gain) on derivative financial instrument" } } }, "localname": "AdjustmentsForGainLossOnDerivativeFinancialInstrument", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_AdjustmentsForResearchAndDevelopmentTaxCreditsReceived": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for research and development tax credits received.", "label": "Adjustments For Research And Development Tax Credits Received", "terseLabel": "R&D tax credits received" } } }, "localname": "AdjustmentsForResearchAndDevelopmentTaxCreditsReceived", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_AlnylamPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alnylam Pharmaceuticals Inc", "label": "Alnylam Pharmaceuticals Inc [Member]", "terseLabel": "Alnylam" } } }, "localname": "AlnylamPharmaceuticalsIncMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares.", "label": "American Depositary Shares [Member]", "terseLabel": "American Depositary Shares" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_AstraZenecaCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AstraZeneca collaboration.", "label": "Astra Zeneca Collaboration [Member]", "terseLabel": "AstraZeneca collaboration" } } }, "localname": "AstraZenecaCollaborationMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_AverageNumberOfEmployeesInAdministration": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails": { "order": 1.0, "parentTag": "ifrs-full_AverageNumberOfEmployees", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Average number of employees in administration.", "label": "Average Number Of Employees In Administration", "terseLabel": "Administration" } } }, "localname": "AverageNumberOfEmployeesInAdministration", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails" ], "xbrltype": "decimalItemType" }, "sln_AverageNumberOfEmployeesInResearchAndDevelopmentAndRelatedSupportServices": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails": { "order": 0.0, "parentTag": "ifrs-full_AverageNumberOfEmployees", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Average number of employees in research and development and related support services.", "label": "Average Number Of Employees In Research And Development And Related Support Services", "terseLabel": "Research and development and related support services" } } }, "localname": "AverageNumberOfEmployeesInResearchAndDevelopmentAndRelatedSupportServices", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfTotalAverageNumberOfEmployeesDetails" ], "xbrltype": "decimalItemType" }, "sln_CapitalLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital losses.", "label": "Capital Losses [Member]", "terseLabel": "Capital Losses" } } }, "localname": "CapitalLossesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_CashAndCashEquivalentsAndUSTreasuryBills": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents and U.S. Treasury Bills.", "label": "Cash and Cash Equivalents and U.S. Treasury Bills", "terseLabel": "Cash and cash equivalents and U.S. Treasury Bills" } } }, "localname": "CashAndCashEquivalentsAndUSTreasuryBills", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_CollaborationAgreementWithHansohMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement with Hansoh.", "label": "Collaboration Agreement With Hansoh [Member]", "terseLabel": "Collaboration Agreement with Hansoh" } } }, "localname": "CollaborationAgreementWithHansohMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_CollaborationAgreementWithMallinckrodtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement with Mallinckrodt.", "label": "Collaboration Agreement With Mallinckrodt [Member]", "terseLabel": "Collaboration Agreement With Mallinckrodt", "verboseLabel": "Collaboration Agreement with Mallinckrodt" } } }, "localname": "CollaborationAgreementWithMallinckrodtMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_CollaborationAgreementWithTakedaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement with Takeda.", "label": "Collaboration Agreement With Takeda [Member]", "terseLabel": "Collaboration Agreement with Takeda" } } }, "localname": "CollaborationAgreementWithTakedaMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_CommitmentOnOfficeRentalAndServiceCharge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitment on office rental and service charge.", "label": "Commitment On Office Rental And Service Charge", "verboseLabel": "Commitment on office rental and service charge" } } }, "localname": "CommitmentOnOfficeRentalAndServiceCharge", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_CommitmentsUnderShortLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments under short leases.", "label": "Commitments Under Short Leases [Abstract]" } } }, "localname": "CommitmentsUnderShortLeasesAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_CommitmentsUnderShortLeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments under short leases.", "label": "Commitments Under Short Leases [Line Items]", "terseLabel": "Commitments Under Short Leases [Line Items]" } } }, "localname": "CommitmentsUnderShortLeasesLineItems", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_CommitmentsUnderShortLeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments under short leases.", "label": "Commitments Under Short Leases [Table]", "terseLabel": "Commitments Under Short Leases [Table]" } } }, "localname": "CommitmentsUnderShortLeasesTable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_ConsultingAndAdvisoryServicesPayableToRelatedPartyPerMonth": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consulting and advisory services payable to related party per month.", "label": "Consulting And Advisory Services Payable To Related Party Per Month", "terseLabel": "Consulting and advisory services payable to related party per month" } } }, "localname": "ConsultingAndAdvisoryServicesPayableToRelatedPartyPerMonth", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_ContractLiabilitiesAdditionsDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract liabilities additions during period.", "label": "Contract Liabilities Additions During Period", "terseLabel": "Additions during period" } } }, "localname": "ContractLiabilitiesAdditionsDuringPeriod", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sln_ContractLiabilitiesNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract liabilities net of tax.", "label": "Contract Liabilities Net of Tax", "terseLabel": "Upfront payments received, net of taxes" } } }, "localname": "ContractLiabilitiesNetOfTax", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_ContractLiabilitiesRevenueUnwoundFromCurrentPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract liabilities revenue unwound from current period.", "label": "Contract Liabilities Revenue Unwound From Current Period", "negatedLabel": "Revenue unwound during period" } } }, "localname": "ContractLiabilitiesRevenueUnwoundFromCurrentPeriod", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesScheduleOfChangeInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sln_CorporateIncomeTaxPayable": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Corporate income tax payable.", "label": "Corporate Income Tax Payable", "terseLabel": "Corporate income tax payable" } } }, "localname": "CorporateIncomeTaxPayable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "sln_CurrentFinancialAssetsAtAmortisedCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current financial assets at amortised cost.", "label": "Current Financial Assets At Amortised Cost [Member]", "terseLabel": "Financial Assets at Amortised Cost - Current" } } }, "localname": "CurrentFinancialAssetsAtAmortisedCostMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_CurrentTaxAssetsForSpecificTaxAccrual": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current tax assets for specific tax accrual.", "label": "Current Tax Assets For Specific Tax Accrual", "terseLabel": "R&D tax credit receivable for specific tax accrual" } } }, "localname": "CurrentTaxAssetsForSpecificTaxAccrual", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_DeferredTaxAssetInRespectOfCapitalLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax asset in respect of capital losses.", "label": "Deferred Tax Asset In Respect Of Capital Losses [Member]", "terseLabel": "In Respect of Capital Losses" } } }, "localname": "DeferredTaxAssetInRespectOfCapitalLossesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_DerivativeFinancialInstrumentsHeldAtFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative financial instruments held at fair value.", "label": "Derivative Financial Instruments Held At Fair Value [Member]", "terseLabel": "Derivative Financial Instruments Held at Fair Value" } } }, "localname": "DerivativeFinancialInstrumentsHeldAtFairValueMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_DescriptionOfAccountingPolicyForBasisOfConsolidationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for basis of consolidation.", "label": "Description Of Accounting Policy For Basis Of Consolidation [Text Block]", "terseLabel": "Basis of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sln_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for basis of preparation.", "label": "Description Of Accounting Policy For Basis Of Preparation [Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sln_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesAndJudgementsAndKeySourcesOfEstimationUncertaintyExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description Of accounting policy for critical accounting estimates and judgements and key sources of estimation uncertainty.", "label": "Description Of Accounting Policy For Critical Accounting Estimates And Judgements And Key Sources Of Estimation Uncertainty Explanatory", "terseLabel": "Critical accounting estimates and judgments and key sources of estimation uncertainty" } } }, "localname": "DescriptionOfAccountingPolicyForCriticalAccountingEstimatesAndJudgementsAndKeySourcesOfEstimationUncertaintyExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sln_DescriptionOfAccountingPolicyForGoingConcernTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for going concern.", "label": "Description Of Accounting Policy For Going Concern [Text Block]", "terseLabel": "Going concern" } } }, "localname": "DescriptionOfAccountingPolicyForGoingConcernTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sln_DirectorIainRossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Director lain ross.", "label": "Director Iain Ross [Member]", "terseLabel": "Director Iain Ross" } } }, "localname": "DirectorIainRossMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_DisclosureOfCapitalCommitmentsAndContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of capital commitments and contingent liabilities.", "label": "Disclosure Of Capital Commitments And Contingent Liabilities [Abstract]" } } }, "localname": "DisclosureOfCapitalCommitmentsAndContingentLiabilitiesAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_DisclosureOfCommitmentsUnderShortLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of commitments under short leases.", "label": "Disclosure Of Commitments Under Short Leases [Text Block]", "terseLabel": "Commitments under short leases" } } }, "localname": "DisclosureOfCommitmentsUnderShortLeasesTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsUnderShortLeases" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfComponentsOfTaxationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of components of taxation.", "label": "Disclosure of Components of Taxation Explanatory", "terseLabel": "Components of Taxation" } } }, "localname": "DisclosureOfComponentsOfTaxationExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfContractLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of contract liabilities.", "label": "Disclosure Of Contract Liabilities Table [Text Block]", "terseLabel": "Schedule of Contract Liabilities" } } }, "localname": "DisclosureOfContractLiabilitiesTableTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfCurrencyRiskExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of currency risk.", "label": "Disclosure Of Currency Risk Explanatory", "terseLabel": "Summary of Currency Risk" } } }, "localname": "DisclosureOfCurrencyRiskExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationAboutCapitalReservesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about capital reserves.", "label": "Disclosure Of Detailed Information About Capital Reserves Explanatory", "terseLabel": "Summary of Capital Reserves" } } }, "localname": "DisclosureOfDetailedInformationAboutCapitalReservesExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about finance and other expenses.", "label": "Disclosure Of Detailed Information About Finance And Other Expenses Explanatory", "terseLabel": "Summary of Finance and Other Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutFinanceAndOtherExpensesExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherExpensesTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationAboutFinancialAssetsAtAmortizedCostExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about financial assets at amortized cost.", "label": "Disclosure Of Detailed Information About Financial Assets At Amortized Cost Explanatory", "terseLabel": "Summary of Financial Assets at Amortized Cost" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialAssetsAtAmortizedCostExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information of other current assets.", "label": "Disclosure Of Detailed Information Of Other Current Assets Explanatory", "terseLabel": "Summary of Other Current Assets" } } }, "localname": "DisclosureOfDetailedInformationOfOtherCurrentAssetsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDetailedInformationOfTradeReceivablesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information of trade receivables.", "label": "Disclosure Of Detailed Information Of Trade Receivables Explanatory", "terseLabel": "Summary of Trade Receivables" } } }, "localname": "DisclosureOfDetailedInformationOfTradeReceivablesExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfDirectorsAndStaffCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of directors and staff costs.", "label": "Disclosure Of Directors And Staff Costs [Abstract]" } } }, "localname": "DisclosureOfDirectorsAndStaffCostsAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_DisclosureOfDirectorsAndStaffCostsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of directors and staff costs.", "label": "Disclosure Of Directors And Staff Costs Explanatory", "terseLabel": "Directors and staff costs" } } }, "localname": "DisclosureOfDirectorsAndStaffCostsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCosts" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfFinanceAndOtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of finance and other expenses.", "label": "Disclosure Of Finance And Other Expenses [Abstract]" } } }, "localname": "DisclosureOfFinanceAndOtherExpensesAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_DisclosureOfFinanceAndOtherIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of finance and other income.", "label": "Disclosure Of Finance And Other Income Explanatory", "terseLabel": "Finance and other income" } } }, "localname": "DisclosureOfFinanceAndOtherIncomeExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncome" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfFinancialAssetsAtAmortizedCostExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial assets at amortized cost.", "label": "Disclosure Of Financial Assets At Amortized Cost Explanatory", "terseLabel": "Financial assets at amortized cost" } } }, "localname": "DisclosureOfFinancialAssetsAtAmortizedCostExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCost" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about unrecognized deferred tax assets.", "label": "Disclosure Of Information About Unrecognized Deferred Tax Assets Explanatory", "terseLabel": "Summary of Unrecognized Deferred Tax Assets" } } }, "localname": "DisclosureOfInformationAboutUnrecognizedDeferredTaxAssetsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfOtherLossesGainsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other (losses)/gains.", "label": "Disclosure Of Other Losses Gains [Abstract]" } } }, "localname": "DisclosureOfOtherLossesGainsAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_DisclosureOfOtherLossesGainsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other (losses)/gains.", "label": "Disclosure Of Other Losses Gains Explanatory", "terseLabel": "Other losses" } } }, "localname": "DisclosureOfOtherLossesGainsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLosses" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfReconciliationOfCurrentTaxCreditExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of current tax credit.", "label": "Disclosure Of Reconciliation Of Current Tax Credit Explanatory", "terseLabel": "Summary of Reconciliation of Tax Credit at Standard Rate of U.K. Corporation Tax to Current Tax Credit" } } }, "localname": "DisclosureOfReconciliationOfCurrentTaxCreditExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfShareCapitalExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure for share capital.", "label": "Disclosure Of Share Capital Explanatory", "terseLabel": "Summary of share capital" } } }, "localname": "DisclosureOfShareCapitalExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of staff costs including directors' remuneration.", "label": "Disclosure Of Staff Costs Including Directors Remuneration Explanatory", "terseLabel": "Summary of Staff Costs, Including Directors' Remuneration" } } }, "localname": "DisclosureOfStaffCostsIncludingDirectorsRemunerationExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfSummaryOfOtherLossesGainsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of other (losses)/gains.", "label": "Disclosure Of Summary Of Other Losses Gains Explanatory", "terseLabel": "Summary of Other Losses" } } }, "localname": "DisclosureOfSummaryOfOtherLossesGainsExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherLossesTables" ], "xbrltype": "textBlockItemType" }, "sln_DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of trade and other payables.", "label": "Disclosure Of Summary Of Trade And Other Payables Table [Text Block]", "terseLabel": "Summary of Trade and Other Payables" } } }, "localname": "DisclosureOfSummaryOfTradeAndOtherPayablesTableTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeAndOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "sln_DistributableReserves": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Distributable reserves.", "label": "Distributable Reserves", "terseLabel": "Distributable reserves" } } }, "localname": "DistributableReserves", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_EffectOfOverseasTaxes": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 5.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effect of overseas taxes.", "label": "Effect Of Overseas Taxes", "negatedLabel": "Effect of overseas taxes" } } }, "localname": "EffectOfOverseasTaxes", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "sln_EquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment and Furniture.", "label": "Equipment And Furniture [Member]", "terseLabel": "Equipment and Furniture" } } }, "localname": "EquipmentAndFurnitureMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "sln_EquitySettledShareBasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity-settled share-based payments abstract.", "label": "Equity Settled Share Based Payments [Abstract]" } } }, "localname": "EquitySettledShareBasedPaymentsAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_EstimatedEmployerTaxObligationOnOutstandingOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated employer tax obligation on outstanding option.", "label": "Estimated Employer Tax Obligation On Outstanding Option", "terseLabel": "Estimated employer tax obligation" } } }, "localname": "EstimatedEmployerTaxObligationOnOutstandingOption", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_EstimatedTaxLossesAvailableForOffsetAgainstFutureProfits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated tax losses available for offset against future profits.", "label": "Estimated Tax Losses Available For Offset Against Future Profits", "terseLabel": "Estimated tax losses available for offset against future profits" } } }, "localname": "EstimatedTaxLossesAvailableForOffsetAgainstFutureProfits", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_FinanceAndOtherIncome": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance and other income.", "label": "Finance And Other Income", "terseLabel": "Total Finance and other income", "totalLabel": "Total Finance and other income" } } }, "localname": "FinanceAndOtherIncome", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeSummaryOfFinanceAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "sln_FinanceAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance and other income.", "label": "Finance And Other Income [Abstract]" } } }, "localname": "FinanceAndOtherIncomeAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_FinancialLiabilitiesPayableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial liabilities payable term.", "label": "Financial Liabilities Payable Term", "terseLabel": "Financial liabilities payable term" } } }, "localname": "FinancialLiabilitiesPayableTerm", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "sln_ForeignTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign tax expense.", "label": "Foreign Tax Expense", "terseLabel": "Foreign tax expense" } } }, "localname": "ForeignTaxExpense", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_FutureTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future tax rate.", "label": "Future Tax Rate", "terseLabel": "U.K. corporation future tax rate" } } }, "localname": "FutureTaxRate", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sln_GeneralInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General information.", "label": "General Information [Abstract]" } } }, "localname": "GeneralInformationAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_GladstoneConsultancyPartnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gladstone consultancy partnership.", "label": "Gladstone Consultancy Partnership [Member]", "terseLabel": "Gladstone Consultancy Partnership" } } }, "localname": "GladstoneConsultancyPartnershipMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_GlobalTargetOnBenchmarkingExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Global target on benchmarking exercise.", "label": "Global Target On Benchmarking Exercise", "terseLabel": "Global target on benchmarking exercise" } } }, "localname": "GlobalTargetOnBenchmarkingExercise", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_GoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill.", "label": "Goodwill [Abstract]" } } }, "localname": "GoodwillAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_GrossProceedsFromIssuanceOfOfferings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of offerings.", "label": "Gross Proceeds from Issuance of Offerings", "terseLabel": "Aggregate gross proceeds from offering" } } }, "localname": "GrossProceedsFromIssuanceOfOfferings", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_GrossProceedsFromIssuanceOfUnderwrittenOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of underwritten offering.", "label": "Gross Proceeds from Issuance of Underwritten Offering", "terseLabel": "Aggregate gross proceeds from underwritten offering" } } }, "localname": "GrossProceedsFromIssuanceOfUnderwrittenOffering", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_GrossProceedsFromTheIssuanceOfPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from the issuance of private placement.", "label": "Gross Proceeds from the Issuance of Private Placement", "terseLabel": "Aggregate gross proceeds of private placement" } } }, "localname": "GrossProceedsFromTheIssuanceOfPrivatePlacement", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_HansohCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hansoh collaboration.", "label": "Hansoh Collaboration [Member]", "terseLabel": "Hansoh collaboration" } } }, "localname": "HansohCollaborationMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_IfSterlingFellTwentyPercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "If sterling fell twenty percentage.", "label": "If Sterling Fell Twenty Percentage [Member]", "terseLabel": "If Sterling Fell 20%" } } }, "localname": "IfSterlingFellTwentyPercentageMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "sln_IfSterlingRoseTwentyPercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "If sterling rose twenty percentage.", "label": "If Sterling Rose Twenty Percentage [Member]", "terseLabel": "If Sterling Rose 20%" } } }, "localname": "IfSterlingRoseTwentyPercentageMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "domainItemType" }, "sln_IncomeFromResearchAndDevelopmentExpenditureCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income from research and development expenditure credit.", "label": "Income from Research and Development Expenditure Credit", "terseLabel": "Income from research and development expenditure credit scheme" } } }, "localname": "IncomeFromResearchAndDevelopmentExpenditureCredit", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_IncreaseDecreaseInCostsCapitalisedInRespectOfIssuanceOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in costs capitalised in respect of issuance of shares.", "label": "Increase Decrease in Costs Capitalised in Respect of Issuance of Shares", "terseLabel": "Costs capitalized in respect of issuance of shares during the period" } } }, "localname": "IncreaseDecreaseInCostsCapitalisedInRespectOfIssuanceOfShares", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "monetaryItemType" }, "sln_IncreaseDecreaseInEquityResultingFromLapseOfVestedOptions": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in equity resulting from lapse of vested options.", "label": "Increase Decrease In Equity Resulting From Lapse Of Vested Options", "verboseLabel": "On options in issue during the year" } } }, "localname": "IncreaseDecreaseInEquityResultingFromLapseOfVestedOptions", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCapitalReservesSummaryOfCapitalReservesDetails" ], "xbrltype": "monetaryItemType" }, "sln_InterestReceivedPaidClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received (paid), classified as investing activities.", "label": "Interest Received Paid Classified As Investing Activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedPaidClassifiedAsInvestingActivities", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_LeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease liabilities.", "label": "Lease liabilities [line items]" } } }, "localname": "LeaseLiabilitiesLineItems", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_LeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease liabilities.", "label": "Lease liabilities [table]" } } }, "localname": "LeaseLiabilitiesTable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_LicencesAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licences and software.", "label": "Licences And Software [Member]", "terseLabel": "Licences and Software" } } }, "localname": "LicencesAndSoftwareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_LicensesAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licenses and software.", "label": "Licenses And Software [Member]", "terseLabel": "Licenses and Software" } } }, "localname": "LicensesAndSoftwareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_MarketCapitalisation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Market capitalisation.", "label": "Market Capitalisation", "terseLabel": "Market capitalization" } } }, "localname": "MarketCapitalisation", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_MarketPriceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Market price of shares.", "label": "Market Price Of Shares", "terseLabel": "Market price of shares (pence)" } } }, "localname": "MarketPriceOfShares", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_MarketPriceOfSharesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market price of shares per share.", "label": "Market Price Of Shares Per Share", "terseLabel": "Market price of shares per share" } } }, "localname": "MarketPriceOfSharesPerShare", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "sln_MaturityOfShortTermBankDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity of short term bank deposits.", "label": "Maturity Of Short Term Bank Deposits", "terseLabel": "Maturity of short term bank deposits and U.S. Treasury Bills" } } }, "localname": "MaturityOfShortTermBankDeposits", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_MilestonePaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment received.", "label": "Milestone Payment Received", "terseLabel": "Milestone payment received" } } }, "localname": "MilestonePaymentReceived", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_NetFinancialAssetsLiabilities": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of assets less the amount of liabilities.", "label": "Net Financial Assets Liabilities", "terseLabel": "Euro denominated net financial liabilities", "totalLabel": "Net financial (liabilities)/assets", "verboseLabel": "U.S. dollar denominated net financial assets" } } }, "localname": "NetFinancialAssetsLiabilities", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "monetaryItemType" }, "sln_NonCurrentFinancialAssetsAtAmortisedCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-current financial assets at amortised cost.", "label": "Non Current Financial Assets At Amortised Cost [Member]", "terseLabel": "Non-current Financial Assets at Amortised Cost", "verboseLabel": "Financial Assets at Amortised Cost - Non-current" } } }, "localname": "NonCurrentFinancialAssetsAtAmortisedCostMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCreditQualityOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_NumberOfBusinessSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of business segments.", "label": "Number Of Business Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfBusinessSegments", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sln_NumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of leases.", "label": "Number Of Leases", "terseLabel": "Number of leases" } } }, "localname": "NumberOfLeases", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sln_NumberOfOperatingSegment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of operating segment.", "label": "Number Of Operating Segment", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegment", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sln_NumberOfReportableSegment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reportable segment.", "label": "Number Of Reportable Segment", "terseLabel": "Number of reportable segment" } } }, "localname": "NumberOfReportableSegment", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sln_OfferingsUnderOpenMarketSaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offerings under open market sale agreement.", "label": "Offerings under Open Market Sale Agreement [Member]", "terseLabel": "Offerings under Open Market Sale Agreement" } } }, "localname": "OfferingsUnderOpenMarketSaleAgreementMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFivePointEightEightAdsOrOnePointNineSixOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at five point eight eight ADS or one point nine six ordinary Share.", "label": "Options Exercised at Five Point Eight Eight ADS or One Point Nine Six Ordinary Share [Member]", "terseLabel": "Options Exercised at $5.88/ADS or $1.96/Ordinary Share" } } }, "localname": "OptionsExercisedAtFivePointEightEightAdsOrOnePointNineSixOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFivePointEightEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at five point eight eight.", "label": "Options Exercised at Five Point Eight Eight [Member]", "terseLabel": "Options Exercised at $5.88" } } }, "localname": "OptionsExercisedAtFivePointEightEightMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFivePointOneTwoAdsOrOnePointSevenTwoOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at five point one two ADS or one point seven two ordinary share.", "label": "Options Exercised at Five Point One Two ADS or One Point Seven Two Ordinary Share [Member]", "terseLabel": "Options Exercised at $5.12/ADS or $1.72/Ordinary Share" } } }, "localname": "OptionsExercisedAtFivePointOneTwoAdsOrOnePointSevenTwoOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFivePointOneTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at five point one two.", "label": "Options Exercised at Five Point One Two [Member]", "terseLabel": "Options Exercised at $5.12" } } }, "localname": "OptionsExercisedAtFivePointOneTwoMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFourPointOneSixAdsOrOnePointThreeNineOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at four point one six ADS or one point three nine ordinary share.", "label": "Options Exercised at Four Point One Six ADS or One Point Three Nine Ordinary Share [Member]", "terseLabel": "Options Exercised at $4.16/ADS or $1.39/Ordinary Share" } } }, "localname": "OptionsExercisedAtFourPointOneSixAdsOrOnePointThreeNineOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtFourPointOneSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at four point one six.", "label": "Options Exercised at Four Point One Six [Member]", "terseLabel": "Options Exercised at $4.16" } } }, "localname": "OptionsExercisedAtFourPointOneSixMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointNineSixOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point nine six ordinary share.", "label": "Options Exercised at One Point Nine Six Ordinary Share [Member]", "terseLabel": "Options Exercised at $1.96/Ordinary Share" } } }, "localname": "OptionsExercisedAtOnePointNineSixOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointNineZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point nine zero.", "label": "Options Exercised At One Point Nine Zero [Member]", "terseLabel": "Options Exercised at \u00a31.90" } } }, "localname": "OptionsExercisedAtOnePointNineZeroMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointSevenTwoOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point seven two ordinary share.", "label": "Options Exercised at One Point Seven Two Ordinary Share [Member]", "terseLabel": "Options Exercised at $1.72/Ordinary Share" } } }, "localname": "OptionsExercisedAtOnePointSevenTwoOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointThreeNineOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point three nine ordinary share.", "label": "Options Exercised at One Point Three Nine Ordinary Share [Member]", "terseLabel": "Options Exercised at $1.39/Ordinary Share" } } }, "localname": "OptionsExercisedAtOnePointThreeNineOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointTwoEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point two eight.", "label": "Options Exercised At One Point Two Eight [Member]", "terseLabel": "Options Exercised at \u00a31.28" } } }, "localname": "OptionsExercisedAtOnePointTwoEightMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtOnePointZeroZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at one point zero zero.", "label": "Options Exercised At One Point Zero Zero [Member]", "terseLabel": "Options Exercised at \u00a31.00" } } }, "localname": "OptionsExercisedAtOnePointZeroZeroMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtSevenPointSixZeroAdsOrTwoPointFiveThreeOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at seven point six zero ADS or two point five three ordinary share.", "label": "Options Exercised at Seven Point Six Zero ADS or Two Point Five Three Ordinary Share [Member]", "terseLabel": "Options Exercised at $7.60/ADS or $2.53/Ordinary Share" } } }, "localname": "OptionsExercisedAtSevenPointSixZeroAdsOrTwoPointFiveThreeOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtSevenPointSixZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at seven point six zero.", "label": "Options Exercised at Seven Point Six Zero [Member]", "terseLabel": "Options Exercised at $7.60" } } }, "localname": "OptionsExercisedAtSevenPointSixZeroMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtSevenPointThreeTwoAdsOrTwoPointFourFourOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at seven point three two ADS or two point four four ordinary share.", "label": "Options Exercised at Seven Point Three Two ADS or Two Point Four Four Ordinary Share [Member]", "terseLabel": "Options Exercised at $7.32/ADS or $2.44/Ordinary Share" } } }, "localname": "OptionsExercisedAtSevenPointThreeTwoAdsOrTwoPointFourFourOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtSevenPointThreeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at seven point three two.", "label": "Options Exercised at Seven Point Three Two [Member]", "terseLabel": "Options Exercised at $7.32" } } }, "localname": "OptionsExercisedAtSevenPointThreeTwoMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtTwoPointFiveThreeOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at two point five three ordinary share.", "label": "Options Exercised at Two Point Five Three Ordinary Share [Member]", "terseLabel": "Options Exercised at $2.53/Ordinary Share" } } }, "localname": "OptionsExercisedAtTwoPointFiveThreeOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtTwoPointFourFourOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at two point four four ordinary share.", "label": "Options Exercised at Two Point Four Four Ordinary Share [Member]", "terseLabel": "Options Exercised at $2.44/Ordinary Share" } } }, "localname": "OptionsExercisedAtTwoPointFourFourOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtZeroPointEightFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at zero point eight five.", "label": "Options Exercised At Zero Point Eight Five [Member]", "terseLabel": "Options Exercised at \u00a30.85" } } }, "localname": "OptionsExercisedAtZeroPointEightFiveMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtZeroPointTwoZeroAdsOrZeroPointZeroSevenOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at zero point two zero ADS or zero point zero seven ordinary share.", "label": "Options Exercised at Zero Point Two Zero ADS or Zero Point Zero Seven Ordinary Share [Member]", "terseLabel": "Options Exercised at $0.20/ADS or $0.07/Ordinary Share" } } }, "localname": "OptionsExercisedAtZeroPointTwoZeroAdsOrZeroPointZeroSevenOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtZeroPointTwoZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at zero point two zero.", "label": "Options Exercised at Zero Point Two Zero [Member]", "terseLabel": "Options Exercised at $0.20" } } }, "localname": "OptionsExercisedAtZeroPointTwoZeroMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtZeroPointZeroFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at zero point zero five.", "label": "Options Exercised At Zero Point Zero Five [Member]", "terseLabel": "Options Exercised at \u00a30.05" } } }, "localname": "OptionsExercisedAtZeroPointZeroFiveMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsExercisedAtZeroPointZeroSevenOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options exercised at zero point zero seven ordinary share.", "label": "Options Exercised at Zero Point Zero Seven Ordinary Share [Member]", "terseLabel": "Options Exercised at $0.07/Ordinary Share" } } }, "localname": "OptionsExercisedAtZeroPointZeroSevenOrdinaryShareMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfDetailsOfSharesIssuedParentheticalDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year eight.", "label": "Options Issued In Year Eight [Member]", "terseLabel": "Options Issued in 2021" } } }, "localname": "OptionsIssuedInYearEightMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year five.", "label": "Options Issued In Year Five [Member]", "terseLabel": "Options Issued in 2018" } } }, "localname": "OptionsIssuedInYearFiveMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year four.", "label": "Options Issued In Year Four [Member]", "terseLabel": "Options Issued in 2017" } } }, "localname": "OptionsIssuedInYearFourMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year nine.", "label": "Options Issued In Year Nine [Member]", "terseLabel": "Options Issued in 2022" } } }, "localname": "OptionsIssuedInYearNineMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year one.", "label": "Options Issued In Year One [Member]", "terseLabel": "Options Issued in 2014" } } }, "localname": "OptionsIssuedInYearOneMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year seven.", "label": "Options Issued In Year Seven [Member]", "terseLabel": "Options Issued in 2020" } } }, "localname": "OptionsIssuedInYearSevenMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year six.", "label": "Options Issued In Year Six [Member]", "terseLabel": "Options Issued in 2019" } } }, "localname": "OptionsIssuedInYearSixMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year three.", "label": "Options Issued In Year Three [Member]", "terseLabel": "Options Issued in 2016" } } }, "localname": "OptionsIssuedInYearThreeMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsIssuedInYearTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options issued in year two.", "label": "Options Issued In Year Two [Member]", "terseLabel": "Options Issued in 2015" } } }, "localname": "OptionsIssuedInYearTwoMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "sln_OptionsOutstandingWeightedAverageYearsToExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options outstanding weighted average years to expiry date.", "label": "Options Outstanding Weighted Average Years To Expiry Date", "terseLabel": "Weighted average years to expiry date" } } }, "localname": "OptionsOutstandingWeightedAverageYearsToExpiryDate", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "sln_OrdinaryEquityShareBasicAndDilutedEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary equity share basic and diluted earnings loss per share.", "label": "Ordinary Equity Share Basic And Diluted Earnings Loss Per Share", "terseLabel": "Loss per ordinary equity share (basic and diluted)" } } }, "localname": "OrdinaryEquityShareBasicAndDilutedEarningsLossPerShare", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDINCOMESTATEMENTS" ], "xbrltype": "stringItemType" }, "sln_OrdinaryEquityShareBasicAndDilutedEarningsLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Equity Share Basic And Diluted Earnings Loss Per Share [Abstract]" } } }, "localname": "OrdinaryEquityShareBasicAndDilutedEarningsLossPerShareAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_OtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other current assets.", "label": "Other Current Assets [Abstract]" } } }, "localname": "OtherCurrentAssetsAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_OtherPensionCosts": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other pension costs.", "label": "Other Pension Costs", "terseLabel": "Other pension costs" } } }, "localname": "OtherPensionCosts", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDirectorsAndStaffCostsSummaryOfStaffCostsIncludingDirectorsRemunerationDetails" ], "xbrltype": "monetaryItemType" }, "sln_OtherThanTradeReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other than trade receivables.", "label": "Other Than Trade Receivables [Member]", "terseLabel": "Other than Trade Receivables" } } }, "localname": "OtherThanTradeReceivablesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_OverdueTradeReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Overdue trade receivables.", "label": "Overdue Trade Receivables", "terseLabel": "Overdue trade receivables" } } }, "localname": "OverdueTradeReceivables", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_PercentageOfEstimatedCostsIncreased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Estimated costs increased.", "label": "Percentage Of Estimated Costs Increased", "verboseLabel": "Percentage of estimated costs increased" } } }, "localname": "PercentageOfEstimatedCostsIncreased", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sln_PercentageOfIncreaseInCurrencyAgainstForeignCurrency": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in currency against foreign currency.", "label": "Percentage Of Increase In Currency Against Foreign Currency", "terseLabel": "Percentage of increase in currency against foreign currency" } } }, "localname": "PercentageOfIncreaseInCurrencyAgainstForeignCurrency", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sln_PercentageOfRevenueIncreased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue increased.", "label": "Percentage Of Revenue Increased", "terseLabel": "Percentage of revenue increased" } } }, "localname": "PercentageOfRevenueIncreased", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sln_PercentageOfShareCapitalOfAnotherEntity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of share capital of another entity.", "label": "Percentage Of Share Capital Of Another Entity", "terseLabel": "Percentage of share capital of another entity" } } }, "localname": "PercentageOfShareCapitalOfAnotherEntity", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sln_PerformanceObligationsWithAstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Obligations With AstraZeneca.", "label": "Performance Obligations With Astra Zeneca [Member]", "terseLabel": "Performance Obligations With AstraZeneca" } } }, "localname": "PerformanceObligationsWithAstraZenecaMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_PerformanceObligationsWithHansohMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Obligations With Hansoh.", "label": "Performance Obligations With Hansoh [Member]", "terseLabel": "Performance Obligations With Hansoh" } } }, "localname": "PerformanceObligationsWithHansohMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_PerformanceObligationsWithMallinckrodtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Obligations With Mallinckrodt.", "label": "Performance Obligations With Mallinckrodt [Member]", "terseLabel": "Performance Obligations With Mallinckrodt" } } }, "localname": "PerformanceObligationsWithMallinckrodtMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_PlacementAgentFeesAndOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Placement agent fees and other expenses.", "label": "Placement Agent Fees and Other Expenses", "terseLabel": "Placement agent fees and other expenses" } } }, "localname": "PlacementAgentFeesAndOtherExpenses", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_PrincipalAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal accounting policies.", "label": "Principal Accounting Policies [Abstract]" } } }, "localname": "PrincipalAccountingPoliciesAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_ProceedsFromPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from private placement.", "label": "Proceeds From Private Placement", "terseLabel": "Proceeds from private placement" } } }, "localname": "ProceedsFromPrivatePlacement", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_ProceedsFromPrivatePlacementNetOfExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from private placement net of expenses.", "label": "Proceeds From Private Placement Net Of Expenses", "terseLabel": "Proceeds from private placement, net of expenses" } } }, "localname": "ProceedsFromPrivatePlacementNetOfExpenses", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_ProvisionRequiredDueToExpectedCreditLossModel": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision required due to expected credit loss model.", "label": "Provision Required Due To Expected Credit Loss Model", "terseLabel": "Provision required due to expected credit loss model" } } }, "localname": "ProvisionRequiredDueToExpectedCreditLossModel", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_PurchaseOfFinancialAssetsAtAmortizedCost": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets at amortized cost.", "label": "Purchase Of Financial Assets At Amortized Cost", "terseLabel": "Purchase of financial assets at amortized cost" } } }, "localname": "PurchaseOfFinancialAssetsAtAmortizedCost", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_RedemptionPurchaseOfFinancialAssetsAtAmortizedCostTermDeposits": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Redemption/(purchase) of financial assets at amortized cost term deposits.", "label": "Redemption Purchase Of Financial Assets At Amortized Cost Term Deposits", "terseLabel": "Redemption of financial assets at amortized cost - term deposits" } } }, "localname": "RedemptionPurchaseOfFinancialAssetsAtAmortizedCostTermDeposits", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_RepaymentOfPrincipalPortionOfLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of principal portion of lease liability.", "label": "Repayment Of Principal Portion Of Lease Liability", "terseLabel": "Repayment of principal portion of lease liabilities" } } }, "localname": "RepaymentOfPrincipalPortionOfLeaseLiability", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_ResearchCollaborationAstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration AstraZeneca.", "label": "Research Collaboration Astra Zeneca [Member]", "terseLabel": "Research Collaboration - AstraZeneca" } } }, "localname": "ResearchCollaborationAstraZenecaMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "sln_ResearchCollaborationIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration income.", "label": "Research Collaboration Income [Member]", "terseLabel": "Research Collaboration Income" } } }, "localname": "ResearchCollaborationIncomeMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_ResearchCollaborationMallinckrodtPlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration - Mallinckrodt plc.", "label": "Research Collaboration Mallinckrodt Plc [Member]", "terseLabel": "Research Collaboration - Mallinckrodt plc" } } }, "localname": "ResearchCollaborationMallinckrodtPlcMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "sln_ResearchCollaborationOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration - other.", "label": "Research Collaboration Other [Member]", "terseLabel": "Research Collaboration - Other" } } }, "localname": "ResearchCollaborationOtherMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "sln_RevenueFromContractsWithCustomersResearchCollaboration": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails": { "order": 1.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 }, "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails": { "order": 0.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from contracts with customers, research collaboration.", "label": "Revenue From Contracts With Customers Research Collaboration", "terseLabel": "Research collaboration - total", "verboseLabel": "Research collaboration" } } }, "localname": "RevenueFromContractsWithCustomersResearchCollaboration", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentReportingSummaryOfAnalysisOfGroupSAssetsAndRevenuesByLocationDetails" ], "xbrltype": "monetaryItemType" }, "sln_RoyaltyIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty income.", "label": "Royalty Income [Member]", "terseLabel": "Royalty Income" } } }, "localname": "RoyaltyIncomeMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_ScheduleOfLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease liability.", "label": "Schedule Of Lease Liability Table [Text Block]", "terseLabel": "Summary of Lease Liability" } } }, "localname": "ScheduleOfLeaseLiabilityTableTextBlock", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseLiabilityTables" ], "xbrltype": "textBlockItemType" }, "sln_ShareBasedPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based payment.", "label": "Share Based Payment [Member]", "terseLabel": "Share Based Payments" } } }, "localname": "ShareBasedPaymentMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_ShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share capital abstract.", "label": "Share Capital [Abstract]" } } }, "localname": "ShareCapitalAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_ShortLeasePaymentsOnPremises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short lease payments on premises.", "label": "Short Lease Payments On Premises", "terseLabel": "Short lease payments on premises" } } }, "localname": "ShortLeasePaymentsOnPremises", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossSummaryOfOperatingLossDetails" ], "xbrltype": "monetaryItemType" }, "sln_SignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies.", "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "SignificantAccountingPoliciesAbstract", "nsuri": "http://silence-therapeutics.com/20221231", "xbrltype": "stringItemType" }, "sln_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sln_SixMonthTermDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six month term deposits.", "label": "Six Month Term Deposits [Member]", "terseLabel": "Six-month Term Deposits" } } }, "localname": "SixMonthTermDepositsMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_StandaloneSellingPricePerTargets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Standalone selling price per target.", "label": "Standalone Selling Price Per Targets", "terseLabel": "Standalone selling price per target" } } }, "localname": "StandaloneSellingPricePerTargets", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_StatementOfFinancialPositionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statement of Financial Position.", "label": "Statement Of Financial Position [Line Items]", "terseLabel": "Statement Of Financial Position [Line Items]" } } }, "localname": "StatementOfFinancialPositionLineItems", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "sln_StatementOfFinancialPositionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statement of Financial Position.", "label": "Statement Of Financial Position [Table]", "terseLabel": "Statement Of Financial Position [Table]" } } }, "localname": "StatementOfFinancialPositionTable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "sln_StockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock conversion ratio.", "label": "Stock Conversion Ratio", "terseLabel": "Stock conversion ratio" } } }, "localname": "StockConversionRatio", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "sln_SummaryOfFinanceAndOtherIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Finance and other income", "label": "Summary Of Finance And Other Income Explanatory", "terseLabel": "Summary of Finance and Other Income" } } }, "localname": "SummaryOfFinanceAndOtherIncomeExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinanceAndOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "sln_SummaryOfOperatingLossExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of operating loss.", "label": "Summary Of Operating Loss Explanatory", "terseLabel": "Summary of Operating Loss" } } }, "localname": "SummaryOfOperatingLossExplanatory", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureOperatingLossTables" ], "xbrltype": "textBlockItemType" }, "sln_TaxCreditReceivable": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax credit receivable", "label": "Tax Credit Receivable", "terseLabel": "(Increase) in R&D tax credit receivable" } } }, "localname": "TaxCreditReceivable", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDCASHFLOWSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "sln_TaxEffectOfResearchAndDevelopmentTaxCreditCurrentYear": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 4.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of research and development tax credit current year.", "label": "Tax Effect Of Research And Development Tax Credit Current Year", "negatedLabel": "Research and development tax credit in respect of current year" } } }, "localname": "TaxEffectOfResearchAndDevelopmentTaxCreditCurrentYear", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "sln_TaxEffectOfUnrelievedTaxLossesNotRecognized": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails": { "order": 2.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of unrelieved tax losses not recognized.", "label": "Tax Effect Of Unrelieved Tax Losses Not Recognized", "negatedLabel": "Impact of unrelieved tax losses not recognized" } } }, "localname": "TaxEffectOfUnrelievedTaxLossesNotRecognized", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationSummaryOfReconciliationOfTaxCreditAtStandardRateOfUKCorporationTaxToCurrentTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "sln_TermDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term deposits.", "label": "Term Deposits [Member]", "terseLabel": "Term Deposits" } } }, "localname": "TermDepositsMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_ThePrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The private placement.", "label": "The Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "ThePrivatePlacementMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_TradeAndOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade and other payables.", "label": "Trade And Other Payables [Member]", "terseLabel": "Trade and Other Payables" } } }, "localname": "TradeAndOtherPayablesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesByCategoryDetails" ], "xbrltype": "domainItemType" }, "sln_TradingLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading Losses.", "label": "Trading Losses [Member]", "terseLabel": "Trading Losses" } } }, "localname": "TradingLossesMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_USTreasuryBillsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S.Treasury bills.", "label": "U.S.Treasury Bills [Member]", "terseLabel": "U.S.Treasury Bills" } } }, "localname": "USTreasuryBillsMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialAssetsAtAmortizedCostSummaryOfFinancialAssetsAtAmortizedCostDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfCategoriesOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "sln_UnderwritingDiscountsCommissionsAndEstimatedOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Underwriting discounts commissions and estimated offering expenses.", "label": "Underwriting Discounts Commissions And Estimated Offering Expenses", "terseLabel": "Underwriting discounts, commissions and estimated offering expenses" } } }, "localname": "UnderwritingDiscountsCommissionsAndEstimatedOfferingExpenses", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_UnderwrittenOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten offering.", "label": "Underwritten Offering [Member]", "terseLabel": "Underwritten Offering" } } }, "localname": "UnderwrittenOfferingMember", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sln_UnrecognizedDeferredTaxAssetsGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized deferred tax assets gross.", "label": "Unrecognized Deferred Tax Assets Gross", "terseLabel": "Total unrecognized deferred tax assets, gross" } } }, "localname": "UnrecognizedDeferredTaxAssetsGross", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "sln_UnrecognizedDeferredTaxAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized deferred tax assets net.", "label": "Unrecognized Deferred Tax Assets Net", "terseLabel": "Total unrecognized deferred tax assets, net" } } }, "localname": "UnrecognizedDeferredTaxAssetsNet", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureDeferredTaxSummaryOfUnrecognizedDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "sln_UpfrontPaymentTaxWithholding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payment tax withholding.", "label": "Upfront Payment Tax Withholding", "terseLabel": "Tax withholding" } } }, "localname": "UpfrontPaymentTaxWithholding", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureTaxationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_UpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payments.", "label": "Upfront Payments", "terseLabel": "Upfront payments" } } }, "localname": "UpfrontPayments", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosurePrincipalAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sln_UsTreasuryBill": { "auth_ref": [], "calculation": { "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "US Treasury bill.", "label": "US Treasury Bill", "terseLabel": "US Treasury Bills" } } }, "localname": "UsTreasuryBill", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "sln_WeightAverageHurdlePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weight average hurdle price.", "label": "Weight Average Hurdle Price", "terseLabel": "Weight average hurdle price" } } }, "localname": "WeightAverageHurdlePrice", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummeryOfFairValueOfOptionsGrantedCalculatedUsingBinomialOrMonteCarloModelAndInputsIntoModelDetails" ], "xbrltype": "perShareItemType" }, "sln_WeightedAverageExercisePriceOfShareOptionsOutstandingInShareBasedPaymentArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of share options outstanding in share based payment arrangements.", "label": "Weighted Average Exercise Price Of Share Options Outstanding In Share based Payment Arrangements", "periodStartLabel": "Outstanding balance, Weighted Average Exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInShareBasedPaymentArrangements", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsSummaryOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "sln_WeightedAverageExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price per share.", "label": "Weighted Average Exercise Price Per Share", "terseLabel": "Weighted average share price" } } }, "localname": "WeightedAverageExercisePricePerShare", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureEquitySettledShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "sln_YearOfIssuanceOfStockOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year of issuance of stock option.", "label": "Year Of Issuance Of Stock Option", "terseLabel": "Year of issue" } } }, "localname": "YearOfIssuanceOfStockOption", "nsuri": "http://silence-therapeutics.com/20221231", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfOptionsOutstandingDetails" ], "xbrltype": "gYearItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialAssetsAndLiabilitiesDenominatedInEurosAndTranslatedIntoSterlingAtClosingRateDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstEuroDetails", "http://silence-therapeutics.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfImpactOfAdditionalWeakeningOrStrengtheningOfSterlingAgainstUSDollarDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFR15_g110-129_IFRS15_g110-129_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_vi&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "24B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "24G", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24G_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B51&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39G", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39G_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r191": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r192": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r193": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r194": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r195": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r196": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r197": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r198": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r199": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r2": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r201": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r202": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r203": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r204": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r205": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r206": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r207": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r208": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r209": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r211": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r212": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r213": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r214": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r215": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r216": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r217": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r218": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r22": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r223": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r224": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r225": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r226": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r227": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "59", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_59_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r228": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r229": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r231": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r232": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r233": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r234": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r235": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r236": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r237": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r238": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r239": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r241": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r242": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r243": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r244": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r245": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r246": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r247": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r248": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r249": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r250": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r251": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r252": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r253": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r254": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r255": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r256": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r257": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r258": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r259": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r260": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r261": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r262": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r263": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r264": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r265": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r266": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r267": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r268": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r269": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r270": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r271": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r272": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r273": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r274": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r275": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r276": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r277": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r278": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r279": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r28": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r280": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r281": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r282": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r283": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r284": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r285": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r286": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r287": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r288": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r289": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r29": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r290": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r3": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "29", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "49", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Section": "Accounting policies", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS08_g7-31__IAS08_g7-31_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }